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A BSTRACT 
Cel Ia  d i  ea e is a common condition that affects al l  populations around the world in al l ages. 
It was thought before that CD is a rare disease effects only the Caucasians mainly in Europe, 
Au tral ia and North America but development of new serological tests lead to increase the 
pre alence of the disease around the world. The main obj ective of this research proj ect is to 
find out the prevalence of latent or si lent cel iac disease among UAE nationals. Total of 1 200 
UAE nationals agreed to participate and answer the questionnaire for the study. Subjects 
isited Al Ain hospital for undergoing prenuptial tests. They were screened for cel iac disease 
using tissue trans glutaminase tTG c lass I gA and IgG then a l l  seropositive cases were screened 
for anti-endomysium antibody (EMA) IgA and IgG and total lgA. 1 4  ( 1 . 2%) of the 1 200 
subjects were seropositive for CD and none of them had been diagnosed before the study as 
CD patient. The prevalence of seropositive CD for females and males was remarkably 
different 1 3/573 (2.3%) female subjects were positive whi le only 1 /624 (0.2%) male was 
positive. Such high difference in prevalence between males and females is remarkable 
compared with many other prevalence studies which mostly reported higher prevalence among 
females but not to the extent of the present study. The unrecognized cases of CD which are 
detected through popUlation screening endorse the concept of celiac iceberg and therefore, 
population screening identifies subjects who could benefit from the treatment. 
IV 
TA BLE OF CONTENTS 
Acknow ledgments.............................................................................................................. 111 
Ab tract............................................................................................................................... IV 
Ta ble of contents................................................................................................................ v 
List of ta bles........................................................................................................................ VII 
List of figu res...................................................................................................................... Vill 
L I INT RODUCTION........................................................................................................ 1 
1 . 1 mall  intestine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . .. . . . . . .  2 
r 1 . 1  Anatorny. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  3 
1 . 1 . 2 Histology of Smal l I ntestine Wal l . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . 5 
A. Epithel ium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  5 
B. Lamina Propria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  6 
C. Muscularis Mucosae. . . . . . . . . . . .. . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ... . . .  7 
D. Duodenal gland (Brunner's). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . .. . .  7 
I . I . 3  Physiology of Small  Intestine. . . .  . . . . .  . . . . .  . . . . . .  . . . . .  . . . . . . . . . . . . .  . . . . . . . . . .  . .. . . .. . . . . . . . . . .. . . . .. . . . . . . . . .  8 
1 . 2  Cel iac Disease. . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . .  . . . . . . . .. . . . . . . .  . . . . .  1 3  
1 . 2 . 1  Brief H istory of Cel iac Disease . .  . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . .  1 3  
1. 2 .2  Epidemiology. . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 5  
1 . 2 . 3  Environmental Factors. . . .  . . . . .  . . . . . . . . . . . . . . . . . . . . .  . . . . .  . . . . .  . . . . . . . . . . .  . . . . . . .. . . . . .  . . . . . . . .  . . . . . . . . . . . . .  20 
1 .2 .4  Genetic  Factors. . . . . . . . . . . . . . . . . . . .  .. . . . . . . . .  . . . . . . . . . . . . . .  . . . . .  . . . . . . .  . . . .. . . . .  . . . . .  . . . . . . . . . . .  . . . . . . . . . . .  . . . .  22 
1 . 2 . 5  Immunological Factors. . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24 
1 .2 .6  C l i nical Presentations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .  28 
1 . 2 . 7  D iagnosis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32 
1 . 2 . 8  Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37 
1. 3 Objective. . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . .  . . . . . . . . . . .  . . . . . . . . . . . .  . . . . . . . . . .  . .. . . . . . . .  . . . . . .  . . . . . .  . . .  . . . . . .  . . . . . . . . . . . . . . .  40 
I I. MAT E R I A LS & METHODS....................................................................................... 4 1  
II.l Subject and Method. . . . .. . .  . .. . .  . .. . . . .. . . . . . . . . . . . . . .  . .. . . . . . . . . . . . . . . .  . . . . . . . .  . . . . .  . . .. . . . .. . .  . . .. . . . . . . . . . . . . . . .. 42 
1 1 . 1 . 1  Study Area. . . . . .  . . .. . . . .. . . . .. . . . . .  . . . . . . . . . . .  . . . . . . . . .  . . . . . . . . .  . . . . . . . . . . . . . . . .  . . . . . . . .  . . . . . .  . . . . . . . . . .  . . . . .  . . .. 42 
I I .l.2 Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42 
v 
I I . 1 . 3 .  Study Population and Blood Sampl ing . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . 43 
I I . l .4 Ethical Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . .  ' " . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . . . .. . . .  . . . .  . . . .  43 
I I -J-5 Serodiagno is criteria . . .  .. . . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  .. . . . .  . . . . . .  . . .  . . . . . . . . . . . . . . . . . . 44 
I I .  2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ' " . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . .  4 5  
1 1 . 2 . 1 Tis ue transgl utaminase tTG- IgA and IgG . . . . . . . . . . . . . . . . . .  '" . . .  . . .  . . . . . . . . . . . .  . . . . .  4 5  
I I .2 .2  Total Human erum IgA . . . . . . . . . . . .  ' " . . .  . . .  . . . . . .  . . .  . . .  . . .  . . .  . . . . . . . . .  . . .  . . . . . .  . . . . . 48 
n .2 .3  Anti- Endomysium Antibody (EMA) . . .  . . .  . . .  . . . . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  50 
1 1 .3 Statistical Analyses . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  . . . . . .  . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  . . . . . .  52 
ID. RESULTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53  
I lL I. Subject characteristics . . . . . . . .  , . . .  . . .  . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  54 
I I I .2 .  Demographi c  Data . . .  . . . . . .  . . . . . . . . .  . . .  . . .  . . .  . . . . . .  . . .  . . . .. . . . . . . .  . . . . . .  . . .  . . .  . . .  . . .  . . .  54 
I I I . 3  Questionnaire Data . . . . . . . . . . . . . . . . . .  ' " . . .  . . . . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . . 5 8  
I Il .4  Serological Results . . .  . . .  . . .  . . .  . . . . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . .  . . . .  5 8  
I lL5 Association o f  Gender and Questionnaire Data with C D  Serology . . .  . . . . . .  . . .. . .  60 
IV . D I SCUSSION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ..... 69 
V. CON C LU S ION & RECOMMEN DATION . .  . . . . . . . . . . . . . . . . . . .  ...................... ..... 76 
VI. RE FE RENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ... 79 
VU. A PP EN D ICES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  88  
Vl 
LIST OF TA BLES 
Page 
Table 1.1 The prevalence of CD according to c l inical diagnosis and screening 1 7  
in western countries 
Ta ble 1.2 E timation of CD prevalence among different populations 1 8  
Table 1 .3 Common signs, symptoms and associated conditions of CD 3 1  
Table 2.1 The acceptable range of tTG IgA calibrators and controls expressed 47 
as OD and U/mi. 
Table 2.2 The acceptable range of tTG I gG cal ibrators and controls expressed 47 
as OD and U/mi .  
Table 3.1 Distribution of age and education according to gender among 57  
sampled subjects. 
Ta ble 3.2 Anti tTG and EMA IgA and IgG antibodies in: 1 4  positive subjects 59 
(serological ly CD si lent or latent); 1 negative (serological ly CD 
free) and 3 excluded subjects on  the basis of  undetermined CD 
serological status. 
Table 3.3 Results of simple logistic regression analyses of CD serology versus 6 1  
gender and anamenistic variables obta ined through questionnai re. 
Table 3.4 Adj usted OR and 95% confidence intervals for cel i ac disease 63 
antibodies in UAE nationals from Al Ain. 
Ta ble 3.5 Distribution of CD serological results and questionnaire data in adult 64 
males and females UAE nationals in AI Ain.  
Ta ble 3.6 Results of simple logistic regression analyses of CD serology versus 66 
anamenistic variables obtained through questionnaire in female 
subjects. 
Ta ble 3.7 Adj usted OR and 95% confidence intervals for cel iac disease 68 
antibodies i n  female subjects. 
Vll 
LIST OF FIGURES 
Page 
Figu re 1 .1 Model used to i l l ustrate that cel iac disease varies with respect to 1 6  
pre entation and se erity of symptoms 
Figu re 1 .2 Immunological reaction against gluten 26 
Figu re 1.3 The different between normal intestinal vi l l i  and complete vil lous 37  
atroph in CD 
Figu re 2. 1 Flow chart for CD serodiagnosis 44 
Figu re 2.2 EMA staining reaction on primate smooth muscle, 200x staining 52 
of l in ing of the smooth m uscle  bundles. 
Figu re 3. 1 Distribution of the UAE national according to the age. 5 5  





Celiac di ease i a chronic inflammatory condition associated with morphological changes in 
smal l  intestine that result in mal-ab orption of different nutrients. It is characterized by an 
inflammatory immune response mainl to ingested wheat gluten. Varied symptoms are 
a sociated with cel iac eli ease, including chronic diarrhea, anemia, and iron and vitamins 
deficiency. Inte t inal biopsy is the golden standard in diagnosis, but should be aided by 
serological test to determine who needs the biopsy and to differentiate the disease from other 
cau es of inte tinal v i l l i  atrophy. 
To our knowledge in UAE no previous published reports on the prevalence of cel iac disease 
in the general population or in high risk group exists. The main objective ofthis research 
project is to find out the prevalence of latent or si lent cel iac elisease among U AB nationals .  
The study wi l l  hopefully form the basel ine for future stuelies targeting high risk groups for 
diagnosis, treatment and fol low up. 
I.ISmall Intestine 
The small intestine is the major digestive organ in the body; after digestion is completed 
absorption occurs with in the smal l  intest ine (Marieb, 200 1 ). The name smal l intestine comes 
from comparing i ts diameter to the large intestine ( I ra, 2004). S ince the eligestion of food start 
in the stomach and completed in  smal l intesti ne, smal l intestine has special factors that play 
major roles in providing huge absorption area ( Young & Heath, 200 1 ). 
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1.1 Anatomy 
The mal l  inte tine is a twisted tube e 'tending from pyloric sphincter in the epigastria 
regton to i leocecal val e in the right i l iac region where it connects to the large intestine 
(Marieb, 200 1 ). The mall inte t ine is the longest region in the al imentary tract of about 7 m 
in length (Gartner & Hiatt, 200 1 )  and the diameter i s  only about 2 . 5  cm (Marieb, 200 1 ). It 
di ided into three subdivision ' duodenum, jejunum and i leum. 
Duoden u m :  First part of the mal l intestine, the length i s  about 20-30 cm and extends from 
the p loric sphincter ( I ra, 2004). The duodenum i s  curve around the beginning of pancreas. 
It is the shortest part of the subdivision (Marieb, 200 1 ). 
Jej u n u m :  Second part of small intestine is about 2 . 5m in  length and extends from the 
duodenum to i leum (Marieb, 200 1 ). 
l leu m : Last part of sma l l  intesti ne and it empties in  the large intestine through the i leocecal 
val e ( Ira, 2004). It is about 3 .6m in length, the jejunwn and i leum coi l  in the central and 
10\ er part of abdomi nal cavity suspended from the posterior or abdominal wal l  by the 
mesentery (Marieb, 200 1 ). 
M icroscopic An atomy 
The small intestine is adapted for nutrient absorption; the length of smal l  i ntestine gives a 
large surface area. The wal l  of i ntestine has 3 modifications to increase the absorption 
surface (Young & Heath, 200 1 ). 
The c i rc u lar  folds (va lves of Kerckring) (also, p l icae c ircu lares) :  are large valvular flaps 
projecting into the l umen of the bowel : They are composed of redupl ications of the mucous 
membrane, the two l ayers of the fold being bound together by submucous t issue. The 
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majority of the c ircular fold extends trans ersely around the cyl inder of the intestine for 
about one-half or two-thi rds of its circumference, but some form complete c irc les, and 
other ha e a piral forms. The larger folds are about 8 mm in depth at their broadest part� 
but the greater number is of smal ler size (Gartner & Hiatt, 200 1 ). The circular folds 
are more d eloped and significant in the jejunum than el sewhere. However, they are 
frequentl pre ent in duodenum and i leum (Carlos & Jose, 2005) .  These folds force chyme 
to move through the lumen and slow the movement to al low for ful l nutrients absorption 
(Marieb, 200 1 ). The second modifications in the wal l  of smal l  intestine are v i l l i .  
Vi l l i: are mucosal surface that look l i ke fmger projections, between each v i l lus mucosa that 
form into crypt cal led Crypts of L ieberkuhn (Young & Heath, 200 1). Each vi l l us contains 
capi l lary loop ending with lymphatic channel ( lacteal ). In these channel the digestive food is 
absorbed through epithelial cel l s  i nto both capi l lary blood and l acteal (Marieb, 200 1 ). Few 
smooth muscles and fibers are placed in loose connective tissue and rich in lymphoid cel l s  
(Gartner & Hiatt 200 1 ). V i l l i  are large in  duodenum (the most active site in  absorption) and 
become narrow and shorter in other part of smal l intesti ne (Marieb 200 1 ). Vi l l i  give velvety 
appearance to the l i ni ng l iving organ (Gartner & Hiatt, 200 1 ). The third modifications in the 
smal l  intestine are microvi l l i .  
M icrov i l l i: are extremely smal l projections o f  plasma membrane of absorptive cel l s  of 
mucosa and sometimes cal l ed brush border (Marieb, 200 1 ). Microvi l l i  are cyl indrical 
projections which are approximately Imm tal l  and O. lllm in diameter (Carlos & Jose, 
2005). The cel l of microvi l l i  conta ins core of actin microfi lament with other cytoskeleton 
protei ns (Carlos & Jose, 2005 ) .  Besides increasing absorption surface area of smal l 
4 
inte tine, micro i l l i ha e enzymes cal led brush border enzymes which complete the final 
tage of digestion of carbohydrates and protein in smal l  intestine (Marieb, 200 1 ). 
1 . 1 .2 Hi tology of m a l l  I n test ine Wa l l  
The mucosa of smal l  intestine is composed from 3 layers, simple columnar epithe l ium, the 
lamina propria and the musculari mucosae (Gartner & Hiatt, 200 1 ). 
A-Epithe l ium:  The epithel ium cel l  types in  the small intestine include enterocytes, goblet 
cel l s  paneth cel ls, M or microfold cel l s, entero-endocrine cel ls, stem cel l and 
intraepithel ial lymphocytes ( Young & Heath, 200 1 ). V i l l i  are covered by simple columnar 
epithe l ium and the intra vil l i  space is composed from previous cel ls  (Gartner & Hiatt, 
200 1 ). 
1 - Surface Absorptive cel l s  or enterocytes cells: are tal l  columnar cel ls  and the main 
absorptive cel ls (Gartner & Hiatt, 200 1 )  enterocytes have oval nucleus in the basal half 
of the cel l;  cel l s  are covered with homogenous layer cal led the stratified brush border 
(Carlos & Jose, 2005) .  The brush border is about 25!lm in length and is densely packed 
of microvi l l i  each absorptive ce l l  contain approximately 3000 microvi l l i  which increase 
the area of contact between intestinal surface and nutrients (Carlos & Jose, 2005). 
Micro i l l i  are covered with thick glycocalyx layer which not only protect the microvi l l i  
from auto-digestion, but also contain enzymes that c leaves dipeptides and disaccharides 
into their monomers (Gartner & Hiatt, 200 1 ). The function of these cel ls is terminal 
digestion and absorption of water and nutrients, conversion of fatty acids to triglycerides 
to form chylmicrons and transport the bulk of absorbed nutrients to the lamina propria 
for di stribution to the rest of the body (Gartner & Hiatt, 200 1 ). 
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2- Goblet cel l . The e cel l  distribute among enterocytes and produce mucin for l ubrication 
the mte tinal content and protect epithel ium (Young & Heath, 200 1 ). Few of them found 
in duodenum and the nwnber of cel l s  increases as they reach the i leum (Carlos & Jose, 
2005). 
3- Paneth Cel ls: Exocrine cel ls with secretary granules in the apical cytoplasm are found 
in the basal portion of intestine glands (Carlos & Jose, 2005)  or located deep in the 
crypt. These cel ls  protect smal l intestine against certain bacteria through releasing 
ly ozymes which is an antibacterial enzymes (Marieb, 200 1 ). 
4- M.  Cel ls  or Microfold cel l :  Specialized epithelial cel ls  covering lymphoid fol l icles of 
payer's patches (Carlos & Jose, 2005 ). They endocytose antigens and transport them to 
the underlying I mphoid cells where immune responses to foreign antigens can be 
initiated. (Carlos & Jose, 2005 ) .  
5- DNES cel ls :  These cel l s  produce paracrine and endocrine hormones, about 1 % of cel ls  
co ering the vi l l i  and intrav i l l i  surface of smal l  intest ine are DNES cel l s  (Gartner & 
Hiatt, 200 1 ). 
B- La m i na propria: core of v i l l i  and from loose of connective tissue which arise above the 
surface of small intestine, the remainder of the lamina propria extends down to the 
m uscularis m ucosa (Carlos & Jose, 2005). The lamina propria is rich in lymphoid cel l  to 
protect the intestine against microorganism. There are certain cel ls  inside lamina propria 
including: 
1 - Crypt of L ieberkuhn or intestinal crypts: its tubular intestinal gland found between 
mucosa of vi l l i  (Marieb, 200 1 ). The vi l l i  of the epithel i um in continuous with that of 
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the gland. The intestinal gland contain ariety of cel ls such as stem cel l s, some 
ab Orptl e cel ls,  goblets cel ls and Paneth cel l s  (Gartner & Hiatt, 2001). 
2- Regenerati e cel l  or stem cel ls: are located at the base of crypts, the cel l  pro ides 
arious epithelium cel ls that migrate up to the vil l i  (Marieb, 200 1 ). These cel ls  replace 
the epithelium of crypts mucosal surface and vil li. The rate of cel l  division is high 
with a short cel l cycle of 24 hours (Gartner & Hiatt, 200 1 ). 
3 - Paneth celJs, located in  the bottom of crypt of  Lieberkuhn, produce lysozymes as 
antibacterial agents (Gartner & Hiatt, 2001 ). 
C- M uscu la ris M ucosa : l ie beneath mucosal crypts and separate mucosa from submucosa 
and is composed of an outer longitudinal layer and an inner circular layer (Gartner & 
Hiatt, 200 1 ). The muscle fibers of the inner circular layers enter the vil lous and extend 
through it cores to the tips of the connective as far as the basement membrane (Gartner 
& Hiatt, 200 1 ). The muscle fibers contract and shortening the vil l us several times 
during the digestive process (Gartner & Hiatt, 2001 ). 
D- Duoden a l  gland (Bru n ner's) a set of elaborated mucus secreting cel l s  found in the sub­
mucosa of the duodenum only (Marieb, 2 00 1 ). The glands neutralize the acidic chyme 
moving from the stomach by the secretion of bicarbonate rich mucosa (Marieb, 200 1 ). 
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I. I.3 Phy iology of Sm al l  I n testi ne 
Onward mo ement of chyme contents produced by segmental and peristaltic movement, 
segmental mo ement is a gentle and propulsion of chyme in smal l intestine (Wilson & Ann, 
1 996). The rate of egmental contraction varies along smal l  intestine; it is high in the 
duodenum and low at the terminal i leum (Davis et aI . ,  200 1). Chyme in segmentation moves 
slowly from section egmentation at high rate to another segmentation rate at lower rate, 
thus the chyme moves in caudal direction where the chyme moves backward and forward 
al lowing for more mixing (Davis et aI . ,  200 1). Another movement of small intestine is 
peristaltic contraction progressive contraction of successive section of circular muscle; it 
in olves only short length of intestine (Berne & Mathew, 2000). Contraction depends more 
on longitudinal muscle than circular m uscle  (Wilson & Ann, 1 996). Absorption of nutrients 
is the main  function of small intestine, the pattern of motil ity of smal l intestine reflects the 
absorption process. Absorption is a process in which molecules after digestion are 
transported through epithel ial cel l  that l ines gastrointest inal tract and then enter blood or 
lymph (Berne & Mathew, 2000). Smal l intestine secretes lot of hormones and enzymes to 
complete chemical digestion of nutrients; the l atter is a l l  processes that aim to change 
chemical state of ingested food. These changes are due to hydrolysis changes when a 
compound unites with water and then spl its to simpler compound (Thibodeau and Patton, 
1 999). 
Since the duodenum is connected to many digestive gland such l iver, gal lbladder and 
pancreas, a l l  products of these glands reach the duodenum (Larsen, 2002). Mucosal l i ning of 
duodenal secrete hormone cholecystokinin CCK hormone to force concentrated bile to be 
released into duodenal l umen ( Larsen, 2002).  CCK produces the contraction of the 
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gal lbladder to increa e the secretions of pancreatic j uice rich in enzyme (Ganong, 2005 ). 
Al 0 CCK enhances the motility of smal l intestine and colon, the secretion of CCK 
increases with contact with digestive products especial ly fatty acid and peptides (Ganong, 
2005 ). When the acid chyme mo es to the smal l  intestine then it mixed with bile, 
pancreatic juice and intestinal juice which incl ude water, mucus, minerals salt and enzyme 
enterokina e (Wilson & Ann, 1 996). Pancreatic juice contain enzyme that breakdown 
carbohydrate (a- amaylase), protein (trypsin, chymotropsin and carboxypeptidases), fat 
( l ipa es, pho pholipase esterases) (Larsen 2002). The pancreas also secretes bicarbonate 
which increase the pH content of duodenum to 7-8 as a favorable pH for the actions of 
these enzymes ( Larsen, 2002). Another honnone is secreted due to presence of the chyme is 
somato tain a growth honnone that inhibits the secretion of another honnone gastrin which 
is secreted in the stomach and inhibits the secretion of hydrochloric acid in stomach 
(Ganong, 2005). When the chyme is in contact with enterocytes of the vil li, the digestion of 
a l l  nutrients is completed, carbohydrates is converted to monosaccharide, protein to amino 
acid, fats to fatty acid and glycerol (Wilson & Ann, 1 996). Most of nutrients are absorbed in 
mucosal lining of duodenum, jej unum and ileum and most of the water that enter the 
duodenum everyday through secretion of gastric and intestinal fluid or direct ingestion 
( Larsen, 2002). 
Each compounds of chyme have different ways for absorption to the lymph and blood. 
Substance moves from the l umen of the intestine into extracel l ular fluid by different 
mechanism, some molecules move by diffusion when the concentration of molecules in the 
gut is higher than in the body fl uid (Davis et aI . ,  200 1 ). Other molecules which are more 
sol uble in water and can't cross cel l membrane transport by facilitated diffusion through 
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channel in the cell membrane (Thibodeau and Patton 1 999). Molecules present at higher 
concentration in the bod fluid than in the intestine or at the same concentration, require 
energy to mo e them up the concentration gradient, a process known as active transport 
which require hydroly i of ATP to dri e movement direct ly or indirectly (Pocock & 
Christopher, 2006). orne molecules depend on complex process for absorption such a 
econdary active tran port that use two processes to absorb nutrients (Thibodeau and Patton, 
1 999). 
Duodenum and upper jejunum have the highest capacity to absorb sugar compared with 
10\ er jejunwn and i leum (Berne & Mathew, 2000). G lucose and galactose as an end 
product of sugar digestion are taken up actively across the brush border plasma membrane 
of epithel ia (Davis et aI., 200 1). Glucose enters the epithel ial cel l  through the l uminal 
membrane by cotransporter molecules which l ink the i nward movement of gl ucose with 
inward movement of Na down its concentration gradients (Davis et aI . ,  200 1). Na enhances 
the absorption of glucose and galactose because the gradient of Na provides the energy to 
mo e both sugars against their concentration gradients. Then both molecules leave the 
intestinal epithel ial cel l  and diffuse into mucosal capi l laries by faci l itated transport (Pocock 
& Christopher, 2006). 
Amino acid and peptides as an end product of protein digestion are transported across brush 
border plasma into intest inal epithe l ium cel ls, through Na dependent co-transport 
mechanism simi l ar to sugar or monosaccharide's. More than 1 0  separate transports have 
been characterized for transport of amino acid (Davis et al., 200 1) .  When amino acids enter 
enterocytes they cross basolateral surface through carriers mediated transport, then amino 
acids enter capi l laries of the vi l l us to the l iver through the portal vein .  Most of amino acids 
1 0  
are ab orbed in  the first part of mall intest ine (Pocock & Christopher, 2006). Smal l  
p ptide hydro] zed b peptida es in the c tosol of smal l intestine so only single amino 
acid appear in the portal blood (Berne & Mathew, 2000) .  Small peptides transport to the 
enterocyte b influx of h drogen ions and once i nside the intracel lular compartment smal l  
peptide broken into amino acid (Pocock & Christopher, 2006). 
Fatty acids, monoglycerides and cholesterol are transported by aid of lecithin and bile salt to 
the intestinal lumen in absorbing cel ls  on v i l l i  (Thibodeau and Patton, 1 999). Small amount 
of fatty acids is absorbed directly from intest inal epithe l ium cel ls into capi l lary blood by 
pas i e diffusion (Pocock & Christopher, 2006). S imple l ipid molecules are released to pass 
through pIa rna membrane by simple diffusion, after absorption most nutrients do not pass 
directly to the general c i rculation. Lacteals conduct the fats along series of lymphatic 
vessels and through many lymph nodes before releasing into the venous blood (Thibodeau 
and Patton, 1 999). L ipid release from the smooth endoplasmic reticulum by exocytosis at 
the basolateral membrane and then enter the lacteals of v i l l i  and leave the intestine in the 
lymph from where they enter i nto venous c irculation via thoracic  duct and avoid the hepatic 
portal vein  (Pocock & Christopher, 2006). 
F l uid and e lectrolytes that generate from ingested food and gastrointestinal secretions are 
absorbed actively along the smal l i ntestine. The absorption of sodium ions is coupled with 
transport of sugar and amino acid, many active sodi um potassi um pumps in the basal 
membrane of intestinal epithel i um cel l  that pump sodium out of the cel l  to create gradients 
that draws sodi um passively along concentration gradients set by absorption of water 
(Thibodeau and Patton, 1 999). Chloride ions transport activel y in lower i leum, b icarbonate 
ions transport actively into the intest inal l umen in exchange of chloride (Davis et aI . ,  200 1 ). 
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Water i absorbed 10 smal l intestine b osmosis into blood vessels responding to the 
gradIents force by the ab orption of ions and nutrients (Pocock & Christopher, 2006). 
Calc lUm ha many processe of transport and absorption, calci urn moves across cell 
membrane by carrier or by channel (Davis et aI . ,  200 1 ). Once calc ium enters the cell it 
binds to protein which rna in 0) es carting calc ium to the basolateral membrane and it is 
exported by actj e transport against concentration gradients (Berne and Mathew, 2000). 
I m m u nologica l Activ i ty of the La m i n a  Propria 
Because of the large mucosal surface of gastrointestinal tract, smal l intestine is exposed to 
many in asi e microorganisms (Carlos & Jose, 2005). The lamina propria is rich in  
lymphocytes mast cel ls, plasma cel ls, leukocytes, fibroblast and sol itary lymphoid nodes 
(Gartner & Hiatt, 200 1 ). The fi rst l i ne of defense is secretion of i mm unoglobul in of the IgA 
c lass. The antigen presenting cel ls  and dendrit ic cel ls of the lymphoid nodes transfer the 
antigen to the lymphocytes to initiate the immune response. Activated lymphocytes move to 
the mesenteric lymph node, then form germinal centers which lead to B cel l  to return to 
lamina propria, where they differentiate into plasma cells that produce immunoglobul in IgA 
(Gartner & Hiatt, 200 1 ). Another protection device is intracel lular t ight j unction that makes 
epithelial cel l a barrier to the penetration of m icroorganism (Carlos & Jose, 2005) .  
1 2  
1.2 eliac Di ease 
Cellae di ea e ha different names celiac in chi ldren, cel iac prue in adult, coel iac disease 
(Briti h p I l ing), non tropical prue, gl uten sensitive enteropathy, idiopathic steatorrhea 
(Holtrneier & Caspary, 2006). 
1.2.1 B rief History of Cel iac Di ease 
Celiac di ea e (CD) appeared when human started cultivating crops ( Wheat, rye, barley) 
after long ears of gathering fruit and hunting animals. The Cultivation of crops began in 
Ferti le Cre cent, the wide belt of Southeast Asia, Ferti le Crescent includes Turkey I ran, 
I raq, Palestine, Syria and Lebanon (Rostami et al. 2004). Then there was a major ancient 
migration from Ferti le Crescent to other parts of world as a result of increased fami ly size 
that demanded new lands. Migration was to the Mediterranean (North Africa, Greece, South 
Europe) Danube Val ley (Central Europe and northern Europe) (Accomando & Cataldo, 
2004). 
The first description of c l inical  entity from Roman Physician Galen named Aretaeus of 
Cappodocia in the second century of AD (Midhagen, 2006). Dr Galen is observation was 
translated by Francis Adams and printed for Sydenham Society in  1 856 . . In 1 9th century Dr. 
Mathew Bai l l i e  publ ished his observation about chronic diarrhea among adult malnutrition 
and abdominal gases and he suggested a rice diet to improve adult health (Guandal ini ,  
2007). 
In  1 888  an Engl i sh Pediatric Physic ian Samuel Gee gave a modem description of CD, by 
using an identical tit le of Francis Adams translation of the Coel iac Affection (Cicl itira & 
Moodie, 2003) .  Dr Samuel Gee bel ieved that diet could cure the patients; he described a 
1 3  
chIld case had Impro ement in his heal th when he ate mussels dai l but he relapsed when 
mus e ls' season ended (Guandalini ,  2007). 
Then man article appeared about CD in the medical l i terature focusing on the c l inical 
feature of disease and manipulating of food as treatment for CD. In  1 924 Dr Sidney Hass 
de cribed a new dietetic treatment that was named a banana diet, a successful treatment 
u ed on 8 chi ldren suffered from anorexia, later children cl in ically cured from CD 
(Guandal im, 2007). The diet excl uded bread, crackers, potatoes and al l cereals. His 
ucce sful treatment was based on el imination of al l  k ind of gluten (Guandal ini ,  2007). The 
banana diet lasted for many years unti l  World War I I, when Dr Dick, a Dutch pediatrician, 
noted impro ement of cel iac chi ldren patients during shortage of cereals and relapse after 
return of bread. Thus, with other doctors in Netherlands they documented for the first t ime 
the role of gluten in wheat and rye in CD. In 1 954 PauUay reported abnormal ity and 
inflammation of the l ining of smal l  intestine seen at operations in adult cel iac patients 
( Midhagen, 2006). I n  1 956 Margot Shiner developed jej unal biopsy to obtain biopsies of 
the l ining of the upper bowel and jej unum safety and quickly from the oral route this 
development al lowed the doctors to l i nk between CD and damage of the proximal smal l 
i ntestine mucosa (Guandal in i ,  2007). By mid of S ixt ies the diagnosis of cel iac was based on 
jej unal biopsies showing atrophy. However, medical communities argue for the diagnosis 
since many of lesions could be caused by different diseases then the diagnosis for CD 
becomes establ i shed as complete c l in ical remission on gluten free diet with documentation 
of normal ization of the lesion and final ly recurrent of lesions once gl uten i s  reintroduced in 
the diet (Guandalini ,  2007). This criterion was proposed in  1 969 by European Society for 
Pediatric Gastroenterology (ESPGHAN) and served the world for over more than 3 5  years 
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(Mulder & Cell ier 2005 . Interlaken Criteria was over looked due to the discovery of 
antlbodie of gl uten in cel iac children which anti-gl iadins antibodies was. In 1 964, Berget 
identified auto-antlbod in the erum of cel iac chi ldren the auto antibody was anti-reticulum 
(Guandal im, 2007). In 1 990 the Interlaken Criteria were reviewed by ESPGAN and new 
diagno es \ ere published about the criteria (Mulder & Cell ier, 2005). The reviewed 
criteria of diagno is of CD was based on abnormal change on biopsy on chi ld with or 
without SignS or symptoms, c l inical ly c lear after gluten free diet associated with 
disappearance of c irculating antibodies. Even after serology tests, diagnosis continued to 
depend on intestinal biopsies (Gunadal ini & Gupta, 2002). After 1 990, CD was known to 
be associated �ith autoimmune disease and associated with specific genes either DQ2 or 
DQ8 and the target auto-antigen was identified as the enzyme tissues trans glutaminase 
(Guandal ini ,  2007). In 200 1 ,  criteria for diagnosis for CD adult have been defined 
anticipation of the 200 1 United European Gastroenterology week ( UEGW) in Amsterdam, 
the diagnosis based on v i l lus atrophy in duodenal histology, crypt hyperplasia and 
intraepithelial lymphocytosis whi le  using diet containing gluten, then normal ize through 
gluten free diet. Serological testing for detection of antibodies before gluten free diet is used 
to support the diagnosis but is not essential . HLA haplotype are circumstantial (Mulder & 
Cell ier, 2005)  
1.2.2 E pidemio logy 
CD disease affect al l  ages in different countries and races. The first study of CD 
epidemiology in  Europe was based on c l inical presentation fol lowed by internal biopsies 
which lead to missing many undiagnosed cases. Wide spread of highly sensitive and 
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pec lfic erologicaJ tests increased the pre alence of disease and also revealed many c l inical 
features of CD (Accomando & Cataldo, 2004). Large cohort studies in Europe and North 
America \i ere done to defined the pre alence of CD where the population have serological 
screenmg for endomy ium or tissue transglutarninase then fol lowed by intestinal biopsy for 
erologlcal positi e individuals, the prevalence was found up to 1 % of West em population 
and there were approximately 7- 1 0  undiagnosed subjects for each known CD (Roltmeier & 
Caspary, 2006). CD is common in Europe, Austral ia and North America. Some studies 
suggested that the prevalence of disease is about 1 :  1 50 - 1 :  300 in UK and in Ireland reach 
1 : 80 - 1 :  1 22 (Cicl i t ira & Moodie, 2003). The finding of screening studies in population of 
I ta l ian school children is up to 1 :200 which is much more than those diagnosed on c l in ical 
basis, these finding proposed analogy of Coel iac I ceberg by Catassi (Mulder & Cel l ier, 
2005)  (Figure 1 1 )  
Figu re 1 . 1 : Model used to i l l ustrate that cel iac disease varies with respect to 
presentation and severity of symptoms (Mulder & Cel l ier, 2005)  
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Table 1 .1: The pre alence of CD according to c l in ical diagnosis and screening in 
\i e tern countries (Guandalini & Gupta 2002) 
Area Pre alence on cl inical Prevalence from 
diagnosis screening 
Denmark 1 :  1 0,000 1 :330 
Finland 1 : 1 000 1 : 1 30 
Germany 1 :2300 1 :500 
I ta l  1 : 1 000 1 :  1 84 
Netherlands 1 :4500 1 : 1 98 
US 1 :  1 0,000 1 :250 
S\ eden 1 : 1 00 
Average 1 :3345 1 : 24 1 
More than 60% of newly diagnosed CD patients are adult; 1 5-20% of them are over 60 
years. CD was described as a disease for European populations but, using the serological 
screening on nontraditional populations lead to discovery of CD cases among them. Study 
in US reported cases of CD among Africans American, Cuban, Dominicans and Asians 
from China and Phi l ippines ( Sharaf el at. , 2004) (Table 1 .  2 ). 
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Table 1.2: Estimation of CD prevalence among different populations (Nlewinski ,  2008) 
Popu lation Estimated Prevalence 
General population 1 in 1 33 
Symptomatic chi ldren 1 in 322 
Symptomatic  adult 1 in 1 05 
Fir  t-degree relatives of people with CD 1 in  22 
Second degree relatives of people with CD 1 in  39 
Chronic disease such (type 1 diabetes ) 1 in 60 
African, Hispanic  and Asian-American 1 in 236 
World wide pre alence l in 266 
In US it was thought that CD is rare disease among population, but finding of multicenter 
studies of CD among population with serology test was 1 :  1 33 (Accomando & Cataldo, 
2004). The studies of prevalence of disease in other countries rather than Europe, Austral ia 
and North America are rare. 2 studies of prevalence of CD in  Lat in America one in 
Argentina and other in  Braz i l ,  the finding of screening 2045 blood donor in  Brazi l has been 
show 1 :68 1 of undiagnosed CD pat ients (Gandolfi et aI., 2000). Whi le  in Argentina 
screening in general population has shown an overa l l  prevalence of 1 :  1 67 (Gomez et a I . ,  
200 1 ). However, any study desi gn for blood donor excl uded the anemic i ndividuals, and 
most of the donors are male, and many studies have found that CD is mainly in anemic 
individuals and female, the rel ation between male and female i s  1 :2 (Accomando & 
Cataldo, 2004) .  But some studies indicate that the effect is equal between male and female 
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(Cic l it ira & Moodie, 2003) .  Since Latin American share Europe ancestry, the prevalence of 
CD should be higher than that in Braz i l ,  the serological test began of both study begin with 
antigJ iadin ant ibod v hich might miss man of undiagnosed of CD (Accomando & Cataldo, 
2004) .  The highest pre alence of CD is among population of refugee chi ldren in North 
Africa 5 .60 0 of aharawi chi ldren have positive endomysi um antibodies (Catassi et a I . ,  
1 999). And this high pre alence of the disease in the world might be due to genetic factors, 
\ here aharawi people ha e high frequency of HLA predisposing genes ( Sharaf et aI . ,  
2004) .  Study on  health blood donor in Tunisia for CD prevalence based on 
anti endomysi um antibodies was 1 : 3 55  or 0 .28%. Researches could not do the duodenal 
biopsy due to donor confidential ity ( Mankai et ai .  2006). On the other part of Africa the 
re ults of CD prevalence was different : none of the 600 i ndividuals in Central Africa has 
been screened for anti endomysium and t issue transgiutaminase antibodies have CD despite 
the introduction of wheat in their diet. This result m ight be due to low prevalence of HLA 
genes among central African population (Accomando & Cataldo, 2004) .  Also CD has been 
reported in Middle East and Arab countries such Kuwait, Saudi Arabia, Lebanon and I raq 
references, these reports based on diagnosis cases and its retrospective Data don 't i nc lude a 
large number of population (Accomando & Cataldo, 2004) .  Furthermore, the reports are 
more related to high risk population of CD such as diabetes type 1 which the prevalence 
among them between 3- 1 0% is higher than the population of Western Countries (Rostami et 
aI . ,  2004). A large serological population screening on healthy blood donor in Iran has been 
revealed a high prevalence of CD reach 1 :  1 66 (Shahbazkhni et aI . ,  2003) .  In North I ndia 
screening of 1 69 fami l i es first degree relatives of CD patients by antitransgultaminase 
antibody have been result to 1 3 .6% where biopsy confirmed only 8.2% (Grover et a l . ,  
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2007). The high pre alence of CD in North India is due to fact the predisposing gene type 
HLA between them (Catassi & Cobel l is, 2007). Also wheat is stable food in north India 
more than Southern where they consume rice more. This explains appearance of CD in 
North India where it is almost near absent in other parts of India where the prevalence 
suggested being 1 :  3 1 0  (Gro er et a l . ,  2007). The prevalence in India suggested being 
increa e due to ri sing of westernization on the diet which depends on wheat (Catassi & 
Cobe l l i  2007). CD is considered rare in East Asia (China, Japan, Korea, Malaysia . . .  etc . )  
becau e rice is the stable diet rather than wheat (Accomando & Cataldo, 2004). 
1 .2.2 E n v i ro n m en ta l  Factors: 
Environmental factors are external triggers for cel iac di sease; these factors include certain 
proteins found in cereals. Cereal products not only trigger inflammatory response leading to 
destroying the small intestinal mucosa but also can lead to gastrointestinal mal ignancy. 
Bread wheat or TritIcum aestivum (originated around 8000 years ago from hybridization of 
TrItICum sp. and T. tauschii (Herpen et aI., 2006) as one of the most important cereal have 3 
basic contents that are separated by mi l l ing: the content inc lude the outer husk or bran, the 
germ and the storage protein structure endosperm or white flour which constitutes 70-72% 
of the whole grain and it is the al lergic component of the wheat (Cicl itira et ai . ,  2005 ; 
Wieser , 2007). 
Wheat can be c lassified according to solubi l ity of its protein contents or the molecular 
weight of the proteins. On the basis of molecular weight wheat can be divided to high 
molecular weight (BMW) containing a large protein belong to glutenins subgroup, medium 
molecular weight (MMW) contain ffi-gl iadins and low molecular weight (LMW) contain 
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mo t of the protein (Cicl itira et aI . ,  2005).  There are 4 groups of protein according to their 
olubi h ty in water, alcohol and salt olution (Wieser, 2007). These proteins groups incl ude 
albumin sol uble water, globul m sol uble in salt o lution, gl iadins soluble in alcohol solution 
and gJutenins msoluble in  water, sal ine or alcohol (Ciccocioppo et aI . ,  2005 ). Gl iadins and 
glutenins, form a gl uten protein which is a storage protein found in cereal grain l i ke wheat, 
rye and barle and form a network in dough (Shewry et at . , 2002) And it is known since 
more than 50  ears ago that gluten is  the trigger of  cel iac disease and both gl iadins and 
glutenins activate the cel iac disease (Dewar et ai . ,  2004). 
Hundreds of protein components are found in gluten, these proteins which are unique in 
their amino acid present either as monomers or l inked by inter-chain disulphide bonds as 
ol igo and polymers ( Wieser, 2007). G luten contains 75% of protein and the rest are starch 
and l ipid. The major type of protein is named Prolamines (Shewry et a i . ,  2002). 
Prolamines are alcohol soluble structure of cereals  which have high content of prol ine and 
glutamine. Other proteins found are secal in from rye, hordein from barley can trigger 
cel iac disease (Ciccocioppo et aI . ,  2005)  G l iadins, gl utenine, hordeines and secal in have 
high contents of pro l ine, which is secondary amide and cause twisting in the polypeptides 
(Dewar et aI . ,  2004). These proteins prevent a complete proteolytic digestion through 
gastric, pancreatic and brush border enzymes in small intestine ( Kagnoff, 2007). Since 
these enzymes are i nsufficient in  prolyl endopeptidase activity these can cause accumulation 
of large peptides fragment with high contents of glutamine and prol ine in smal l intestine 
(Kagnoff, 2007). On the bases of N- term inal amino acid sequences gl iadins are designated 
as (1-, �, y- and ill-types (Cicl itira & Moodie, 2003;  Ciccocioppo et a I . ,  2005). The peptide 
corresponding to amino acid residues 3 1 - 49 of A- gl iadins was found to cause histological 
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damage in mall intestine specimens (Cicl itira & Moodie, 2003). Only gliadin has been 
in e tigated in detail as trigger of cel iac diseases (Ciccocioppo et aI . ,  2005) .  New analytical 
methods appl ied for gl iadins such as two dimensions electrophoresis or reversed phase high 
performance l iquid chromatography (RP- HPLC) al lowed the separation of gl iadins fraction 
into more than hundred component based on analysis of partial or complete of amino acid 
equence and molecular weight (Wieser, 2007). Gl utamine fraction contains aggregated 
proteins connected together by disulphide bond, the size is ranging between 500,000 to 1 0  
mi l l ion glutenine subunit have been divided into high molecular weight HMW subunit 
( MW = 67,000-88 000) and low molecular weight LMW subunits ( MW= 32, 000-35 ,000) 
(Wieser 2007). Some studies indicate that low, high molecular gl utenine stimulate the 
disease (Koning et aI . ,  2005). These problematic subdivisions and subgroups reflect the fact 
that each wheat variety expresses a large number of related proteins which make study of 
biochemical , toxicity and gene mapping a difficult task (Cicl itira et aI . ,  2005). 
1.2.4 Genetic Factor 
There are many of evidences that l ink CD pathogens to genetic  factors. These evidences 
include observation of multiple cases of CD among fami l ies (Kagnoff, 2007). Around 75% 
of CD within identical twin have high rate of co-ordinance of CD (Woodward, 2007) 
comparing to 20% in dizygotic (Clot & Babron, 2000) .  Fami ly  studies indicate that the risk 
of CD in first degree relatives being 20-30% time greater than general population (Dewar et 
aI . ,  2004) and the disease occur in 1 0% of first degree relatives. In 1 972 there was first 
report of relation between CD and HLA complex , the relation was discovered through a 
serological method (Heel et a I . ,  2005),  CD is connected to the specific major 
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histocompatabil ity MHC c lass I I  al leles that maps to the HLA-DQ locus (Kagnoff, 2007). 
MHC is the c luster of genes that display cell associated antigen for recognition by T cel l  
(Abbas & Lichtman 2005). MHC is  referred to as HLA complex in humans which divides 
into 3 classe of molecule one of them c lass I I  MHC genes that express mainly on antigen 
presenting cel l  APC such macrophage, dendritic cel l  and B cel l  where they present 
proc ssed antigenic peptides to TH cell (Goldsby et aI . ,  2003). The genetic factors of HLA 
comple \ as estimated to account for 50% of genetic load of CD (Tol lefsen et aI . ,  2006). 
Two al lele encode specific HLA the HLA -DQ2 and HLA- DQ8 heterodimer that confer 
relatively higher risk to CD are formed by P and a. chain (Heel et ai . ,  2005 ). P chain encoded 
by al leles HLA - DQP*02 (Either HLAP I *202 or 203) and a. chain encoded by al leles 
HLA- DQA l *05 ) ( Kagnoff, 2007). About 95% of CD patients carry a different of DQ2 
encoded b_ DQA l *5/ DQB*2 and the remaining of cel iac patients carry DQ8 encoded by 
DQA I *03/DQB l *0302 ( Vader et aI . ,  2003 ; Tol lefsen et aI . ,  2006). DQ2 can be encoded CIS 
i n  same haplotype or rarely i n  tran , the monomer subunit are encoded on separate 
haplotype both cis and trans are different in one of amino acid which does not affect the 
disease risk ( Heel et a I . ,  2005). Another relation of genetic  factor to the CD is  autoimmune 
disease such type 1 diabetes melli tus, rheumatoid arthritis share CD the HLA complex 
(Dewar, 2004). 50% of the genetic load is referred to as the HLA complex and about 30% 
of health Caucasians carry the HLADQ2 ( Heel et a I . ,  2005) .  These finding suggest that 
carrying HLA complex is not sufficient to cause CD but is necessary, and there are another 
genet ic factors partic ipate in disease. To identify other genetic  factors genome wide l inkage 
studies have been performed in different population in Europe. These studies based on 
analysis of nuclear fami l ies affected by CD in different countries (Clot & Babron, 2000). In  
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tud. performed in Dutch two loci are identIfied for CD located in  chromosomes 5 and 1 9  
(Heel et aI . ,  2005) .  Other candidate genes found on chromosomes 2,3,4,5,6, 1 1 ,  1 8  and 1 9  
(Kagnoff, 2007). Some candidate genes belong to immunity response such CTLA- 4 
cytotoxic T lymphocytes (C lot & Babron 2000). However, these genes have low risk of CD 
e posed comparing to e pressing of DQ2 and DQ8 (Kagnoff, 2007). Some genes are 
identified I n  orne population but not a l l ;  therefore, more studies are needed to identify 
more accuratel the predisposing genetic factors for CD. 
1 .2.5. I m m u nological Facto rs 
Gluten protein can activate innate and adaptive immunity arms of the immune system. The 
innate immune or the natural immunity is referred to as non specific, rapid and without 
memory immunity (Goldsby et aI . ,  2003) .  In CD the innate cel l s  release cytokines that 
regulate and coordinate many activities of the cel l s  of the adaptive i mmunity (Abbas & 
L ichtman, 2005 ). I nterleukin 1 5  ( I L- I 5 ) is one of the cytokine released by many cel ls  but 
mainly dendrit ic cel l s  that stimulate, prol iferate develop and activate of T cel ls (Goldsby et 
a t . ,  2003). Adaptive immunity is mediated by lymphocytes and is more specific and has 
memory (Abbas & Lichtman, 2005). In CD the adaptive immunity mediated through T cel l s  
which b ind to HLA loaded by gluten peptides. According to Kagnoff, 2007, the immuno­
pathogenesis model of the T cel l  response in CD is divided to the 3 phases; early event 
located in Lumina and mucosal ,  activation of the pathogenic CD4 and event that lead to 
tissue damage. 
Early event in l umina and mucosa l : Gl uten is digested through gastrointestinal enzymes to 
peptides (Koning et at. ,  2005). S ince there is l ack of prolyl endopeptidases 
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m ga tric ,  pancreatic and brush border large peptides of gl uten which is rich in prol ine and 
glutamme remain after initial digestion (Koning et at . ,  2005). In individuals with increase 
u ceptlbl l ity to CD because of genetic, immunological or environmental event ( infection 
with enteric virus) peptides of gluten actj ate series of immunological events that lead the 
digested peptide attached to antigen presenting cel ls in subepithel ial region of the smal l  
intestine to  many pathwa s· may include the uptake of peptides by dendrites cel l process 
that cros the epithe l ial cel l  layer or faci l itated by the uptake of gluten peptides to smal l  
inte t ine mucus by oral infection or any other infection that cause inflammation , then 
gluten peptides bound to HLA DQ2 or DQ8and this activates gluten specific CD4 mucosal 
T cel l  which activate TH cytokine production, last stage of immuno-pathogenesis is 
re leasing of cytokines such I FN-y and others lead to continue response and change key 
mucosal function incl uding intestinal permeabi l i ty can also lead to activation and release of 
enzymes that can damage the mucosa, resulting in loss of vi l l i  structure and crypt 
hypertrophy ( Kagnoff, 2007) ( Figure 1 . 2 ). 
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This schematic di i des the pathogenesis of CD into 3 major series of events: l uminal and 
early mucosal events; the activation of pathogenic CD4+ T cel ls; and the subsequent 
events leading to tissue damage. During the l uminal and early mucosal events, key features 
include the i ngestion of "gluten" by a genet ical ly susceptible individual . "Gluten' is not 
fu l ly digested because of its high prol ine content, and this gives rise to a number of large 
undigested "gluten ' peptides. The peptides cross the epithel ial barrier to the lamina propria 
and encounter tissue TGase and APCs that express HLA-DQ2 or HLA-DQ8 heterodimers 
that are ideal ly suited to bind prol ine-rich peptides containing negatively charged gl utamic 
acid residues as a result of gl utamine deamidation by ti ssue TGase. In  a further series of 
events, the APCs present some of these peptides to HLA-DQ2- and HLA-DQ8-restricted 
populations of CD4+ T cel ls that become activated and release mediators that ultimately 
lead to tissue damage. There are sti l l  many unknowns. These include the mechanism by 
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which "gl uten" peptides cro s the epithelial cel l barr ier, the role of innate immunity and 
IELs 10 both the earl and the late phases of CD pathogenesis, the role of I L- 1 5  and type I 
IFN in di ease pathogene i s, the underlyi ng basis for the release of tissue TGase that leads 
to dearnidation of gluten peptides, and the sequence of, and relationship between, CD4+ T 
cel l re pon e and the responses of the IEL population (Kagnoff, 2007). 
CD i con idered as an autoimmune disease in which response to self  ti ssue leading to tissue 
damage, there are autoantibodies that able to react to self  components (Delves et aI . ,  2006). 
Self antigen can't easi ly be e l iminated comparing to e l imination of strange invaders, an 
autoantigen presence in the body leading to production of more autoantigen as a result of 
tissue damage (Janeway et aI . ,  2005 ). Interaction of nonspecific effectors cel ls  such as 
macrophages and neutrophi ls  that respond to release of cytoki nes and chemokines, thus, the 
self  destructive process is continuing ( Janeway et aI . ,  2005) .  Autoimmune diseases have 
geneti c  factors and tend to be found in certain fami l ies or c luster in one person; there is 
more chance of havi ng autoimmune disease in  both identical twins than non identical twins 
(Janeway et aI . ,  2005;  Delves et a I . ,  2006). Risk of getti ng an autoimmune disease is 
associated with presence of H LA genes, the relative have high r isk of the particular disease 
by comparing to the disease frequency among the carriers of particular HLA genes with the 
frequency of the disease among non carriers (Doah et aI . ,  2008). Moreover, most of the 
autoi mmune disease is l inked strongly to MHC c lass I I  a l leles. This rel ation between M HC 
and autoimmune disease relate to the fact that immune response is required. T cel l  and its 
abi l ity to recognize particular antigen is dependent on the MHC molecule haplotypes 
(Janeway et a I . ,  2005). Many autoimmune diseases are more common in females than males 
and this due to unknown factors (Goldsby et a I . ,  2003). Environmental factors influence 
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gett ing autoimmune di eases, there are e idence in animals models that some kind of toxins 
in the en ironment can lead to autoimm une disease such heavy metals gold and mercury. In  
Animal model both of those heavy metals when administrated to genetical ly susceptible 
strains of mice lead to autoantibod production which fit with the CD model ( Janeway et 
aI . ,  2005). 
I.2.6.Cl i n ica l Presentation 
A lot of c l inical presentations are as ociated with CD patients. The symptoms of cel iac are 
manifested in adult at the fourth or fifth decade. On other hand, the symptoms can occur in 
chi ldren in  early l i fe then subside for many years then reappear again in  adulthood. Some 
researches refer to physical or emotional stress that leads to sing and symptoms become 
noticeable in adulthood after existing sub c l inically for years ( Early,2005). Most of c l in ical 
presentations are due to intest inal features and those caused by mal-absorption of nutrients 
and vitamins (Holtmeier & Caspary, 2006). However, the presentations of disease depend 
on cases and particular practice of patients (Westerberg et a l . ,  2006). Symptoms of CD are 
very broad spectrum of cl inical features. C l inical presentation of CD has been divided into 4 
categories these categories inc lude typical, non typical, si lent and latent. Typical 
presentation refers to CD patients suffering from gastrointestinal manifestation such as 
diarrhea, abdominal pain, distension, weight loss, steatrohoea, constipation and i ndigestion 
(Jones et aI, 2006; Westerberg et aI, 2006). Non typical CD patients refer to patients who 
present extraintesti nal symptoms such immunoglobul in  I gA, nephropathy, hemosiderosis of 
l ung (Holtmeier & Caspary, 2006). Less common manifestation include neurological 
condition such ataxia, dementia, and epilepsy (Early, 2005 ). The term si lent refers to 
patients asymptomatic who appear healthy and l ack diarrhea (Holtmeier & Caspary, 2006, 
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Jones et aI . ,  2006). Moreover, many CD si lent patients ha e minimal or no abnormalities in  
I l lou tructure (Freeman et aI . ,  2002). But the patient are positive in serology test and 
t pical HLA predisposing ( Fasano & Catassi 2005 ). The term latent refers to individuals 
who wi l l  de elop the disease later on l ife and they have positive serology test and HLA with 
no abnormalities of i Uous and i t ' s  unknown what trigger the symptoms for these 
indiVIdual (Holtmeier & Caspary, 2006). Mode of CD presentation have been changed, 
tud of 2S2 cel iac patient in adult in Italy revealed that only 43% of them show classic 
gastrointest inal  symptoms due to deficiency of nutri t ion's  such as i ron, calcium, fol ic and 
depletion of mineral and ions such as potassi um, zinc and magnesium (Early, 2005). Some 
patients present 0 erweigh, reflecting the obesity tendency in some i ndividuals ( Furse & 
Mee, 2005). 
Females differ i n  their presentation for CD than male, symptoms present more sever, 
di erse and rapid symptoms at younger age (Early,200S), some studies indicate that females 
ha e high risk of suffering from miscarriage, low birth weight chi ldren (Cicl it ira & Moodie, 
2003)  and CD might responsible of unexplained inferti l ity (Guandal in i  & Gupta, 2002). The 
rel ation between severity of symptoms' and the v i l lous atrophy are sti l l  conversional, some 
studies refer that the severity of symptoms is not necessari ly proportional to the severity of 
mucosal lesion; patient might have total v i l lous atrophy and can be asymptomatic  or present 
with subc l i nical symptoms such muscle  cramps and i ron deficiency (Holtmeier & Caspary, 
2006). Whi le  some studies refer that the severity of symptoms and mal-absorption are 
directly influenced by degree of enteropathy (Westerberg et at . ,  2006). 
There are associations between CD and some disease in adult such dennatitis herpertiformis  
which is the most common disease for CD and effect 25% of patients (Westerberg et  aI . ,  
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2006 ) Dennatitis herpertifonni is  skin disorder associated with vi l lous eruption on the 
elbow , buttocks and back, and it has been seen that conditions respond to gluten free diet 
(We terberg et aI . ,  2006). Other disorder are autoimmune thyroid disease, thyroid 
lymphoma, type I diabetes mel l itus, autoimmune l iver disease and inflammatory bowel 
disea e ( Freeman et aI . ,  2002). The longer exposure to gluten is l inked to higher incidence 
of autoimmune disorder (Westerberg et al . ,  2006). The pathogenesis of autoimmune thyroid 
disease and CD are not known, but it was known that all these condition sharing same fll..A 
haplotype and are associated with encoded cytotoxic T lymphocytes associated antigen 
(Ch'ng et a l .  2007). CD also common for individuals suffer from IgA deficiency, However, 
no difference for c l inical presentation between them and other CD patients, but there an 
over pre entation of si lent and atypical symptoms was observed among them (Dahlbom et 
aI . ,  2005)  as shown in (Table l .  3 ). 
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Tab le 1 .  3: Common ign , symptoms and associated conditions of CD 
(Westerberg et aI . ,  2006). 
I Co m mo n  Associa ted Cond it ions wi th 
CD 
Autoimmune Di order 
Type 1 diabete mel l i tus 
Dermatitis 
Down s ndrome 
Epi leps 
Immunoglobul in  A deficiency 
Osteoporosis or other bone disease 
Signs a n d  Sy m ptoms of C D  in Adul t  
Abdom inal Pain 
Chronic diarrhea 
Inferti l ity or recurrent spontaneous 
abortion 
I ron deficiency anemia 





Patients with CD have high risk to develop bone metabol ism (Jones et aI . ,  2006). Other 
complications include developing esophageal cancer, melanoma and smal l intestine 
adeonocarc inoma (Westerberg et aI . ,  2006). In general, people with CD are at modestly 
increase risk of mal ignancy and mortal ity compared with general population (West et aI . ,  
2004) .  O n  other hand, some studies suggest more than modest increase i n  mortal ity and 
mal ignancy among CD patients compared to the general population (West et aI . ,  2004). 
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1.2.7 Diagno j 
The diagnosis for CD I usual ! the target of individuals who have c l inical presentation or 
condItIOn a soclated with CD· ph ician must consider testing the asymptomatic individuals 
who are m highe t risk of developing the disease (Westerberg et ai . ,  2006) .  The high risk 
group of ha ing CD inc lude the first relati es degree of CD patients, type I diabetes 
mel l itus, Down syndrome, autoimmune thyroiditis , unexplained metabolic of bone disease 
i rritable bowel syndrome, chronic li er of unknown functional dyspepsia, unexplained 
fatigue and neurological disorder (Early,2005 ; Westerberg et a I . ,  2006). Beside individuals 
with manifestation of mal-absorption of nutrients and mineral such iron, fol ic acid, calcium, 
i tamin K, D, E and unexplained weight loss (Green et aI . ,  2005) .  Also females with 
inferti l ity or miscarriages should be considered by physicians as a high risk group (Mulder 
& Cel lier, 2005). 
CD patients produce amount of immunoglobul in such IgA, IgG and I gM and other 
antibodies against reticul um, gl iadins, endomysium and t issue transglutaminase, these 
finding lead to i ntroduce serology tests to detect antibodies against CD (Early,2005) .  The 
serological tests are simple, not expensive and require blood serum only  and it 's widely 
avai lable. Some studies suggest that patients with low to moderate probabi l ity of having CD 
can be subjected to serology screen rather than biopsy (Abdul Karim & Murray, 2003). 
Serology tests are helpful for high risk patient and to monitor the adherence to gluten free 
diet (Abdul Karim & Murray, 2003). 
Anti gl iadins antibody (AGA) i s  the first serology test that has been introduced in  early 
1 980 for CD diagnosis. AGA detects the antibodies in serum and is widely avai lable and 
not expensive (Guanda l ini & Gupta, 2002). The test measures two type of immunoglobul in  
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IgA and I gG.  The most sensitive tests are based on use I gA isotype, IgG AGF have been 
found in 30% of controls; therefore, a positive test is of l ittle value (Guandal ini  & Gupta, 
2002 ; Green et aI . ,  2005) .  The speci ficity i s  different depending on the laboratory centers 
some the range refer 82- 1 00% (Guandalini & Gupta, 2002 ; Early, 2005); whi le  the 
ensiti I ty is low and it ranges between 70 -92% (Guandal ini  & Gupta, 2002 · Early, 2005;  
Green et aI . ,  2005 ). Because of the low sensitivity of AGA and discovering of new more 
accurate tests the test is no longer used l ike before· the test is main ly used now to monitor 
response to the GFD (Abdul Karim & Murray, 2003 ). Another l imitation for the AGA is 
due to the presence of the antibodies in healthy individuals and in the inflammatory bowel 
syndrome (Westerberg et aI .  2006). There are no reference on the sensitivity and 
specificity of anti-reticulum antibodies test (Green et a l . ,  2005 ). The Second test avai lable 
for CD screening is endomysium antibodies EMA, a connective tissue protein  found in the 
matrix of monkey and human ti ssue (Abdul Karim & Murray, 2003)  The test is based on 
immunolforescence using monkey esophageal section or human umbi l ical cord smooth 
muscle  as antigen source and sera from patient bei ng tested (Guandal ini & Gupta, 2002). 
The test has high speci ficity that reach up 1 00% in some studies, the sensitivity reach 90%. 
The high specificity and sensitivity lead some investigators to suggest that there is no need 
for biopsies with positive EMA (Freeman et aI . ,  2002; Guandal in i  & Gupta, 2002; Abdul 
Karim & M urray, 2003; Green et aI . ,  2005) .  However, the test is expensive and requires the 
use monkey esophagus which is endangered species or using human umbil i cal  cord as 
substrate that l im it the screen for the large population (Guandal ini & Gupta, 2002 · Green et 
aI . ,  2005) .  Also it requires technical experience i n  performi ng the test (Abdul Karim & 
Murray, 2003) .  Besides that reason the presence of EMA correlates with degree of vi l l us 
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atroph ( Mulder & Cel l ier, 2005 ). The sensitivity of the test reachs 1 00% when using 
umbI l ical cord and human jej unum as substrate but is  less when individuals ha e Jess severe 
degree of mal l  intestine i l l us atroph (Abdul Karim & Murray, 2003 ). 
The newest test for CD screening is anti-tissue transglutaminase antibodies anti-tTG. Tissue 
transglutaminase is intestinal enzymes release from injured cel l s, the enzymes l ink with 
gl iadins to become a target of antibodies response the mucosal injury stop when el iminati ng 
g \ ladin (Earl ,2005 ). In 1 997 Dieterish and col l eagues identified tTG as the autoantigen of 
CD or for EMA (Abdul Karim & Murray, 2003 ). This discovery a l lowed to develop 
Enzyme Linked Immunoabsorbent Assay (ELISA) the antigen first was derived from the 
guinea pig l iver the sensitivity for guinea pig 19A tTG antibodies was found to be 98% 
whi le specificity \ as found to be 94% in patient with biopsies proven CD (Guandalini & 
Gupta, 2002). Then the test is replaced with human tTG an antibody is better perfonned 
than guinea pig (Green et al . ,  2005 ). The test detects both immunoglobul in IgA, IgG ,  
sensitivity of  human tTG is  more than 90% but the specificity is  l ess than EMA (Green et 
a l . ,  2005) .  The test based on ELISA and it is not cost ly and not t ime consuming compared 
to EMA (Guandal in i  & Gupta, 2002). The serology test of EMA and tTG are l imited due 
to many factors, both tests are underestimating the prevalence of CD by 20-25% , i ncaution 
of patients with mi ld  mucosal change i n  this situation patients can't express EMA or tTG 
and the mucosal lesion become less express (Green et al . ,2005 ). Seronegative results have 
been found for smoking individual . Furthennore, most studies have been perfonned on high 
CD prevalence group, thus, the positive predictive value of test i s  lower than reported when 
the serology tests is appl ied in general population ( Mulder & Cel l ier, 2005). About 2-6% of 
diagnostic CD individuals have 1 9A deficiency that occurs mainly in CD patients (Dahlbom 
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et aI . ,  2005). Therefore, the patient lack IgA in AGA, tTG and EMA and the serology test 
become negati e (Abdul Karim & Murray, 2003 ) Te ting for IgG antibodies in association 
with total Human IgA is more rel iable for IgA deficiency (Guandalini & Gupta, 2002). 
HLA D 2 or HLA D08 al leles are found in more than 40% of population and it appears 
that the test for HLA typing is necessary but not sufficient by its own as there are high 
negative predicti e values of CD (Green et aI . ,  2005) .  The test i s  used to identify individuals 
at high risk to develop CD (Westerberg et aI . ,  2006); it i s  good in diagnosis of first degree 
relatives. Moreover, the test is required when diagnosis not confirmed by other tests and the 
absence of DQ2 or DQ8 rule out the disease (Abdul Karim & Murray, 2003) .  
Biops of small i ntesti ne is the golden standard for confirming the diagnosis of CD and 
therefore positive serology results should be confirmed by biopsies ( Freeman et aI . ,  2002; 
Guandal in i  & Gupta, 2002). The goal from biopsy is to recognize the v i l lous atrophy in 
mucosal specimens ( Westerberg et aI . ,  2006). Most biopsy is performed during upper 
endoscopy; b iopsy should be obtained from the second or third section of distal duodenum 
to a oid architectural changes of duodenal gland (Brunner's) ( Westerberg et a I . ,  2006). 
Several studies have compared duodenal biopsies with section of jej unal biopsies in the 
same patients and found that there is rarely any difference between the sections (Abdul 
Karim & Murray, 2003)  Several abnormal change might be seen in i ntest inal biopsy, these 
changes include i ncrease number of the lymphoid cel lu lar element in the lamina propria, 
increase of i ntraepithel ial lymphocytes, i ncrease cuboidal surface of epithel ial cel l  rather 
than columnar epithe l ial cel l ,  hyperplasia with increase epithel ial cel l (Freeman et al. , 
2002). In  1 990 Marsh prove a spectrum on consecutive stage of mucosal abnormal ities that 
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can be een in CD patIents. This reveal to Marsh Clas ification of smal l intest ine lesion 
(Mulder & Cel1 ier, 2005). The tages of classification are as fol lows: 
tage 0 i characterized by pre infiltration mucosa (Abdul Karim & Murray, 2003) Marsh I 
i characterized by lesion architecture of the mucosal look normal and the mucosal 
epi thel i um is in aded b I mphocytes and infiltration of the lamina propria (Mulder & 
Cel l ier, 2005). These changes can be seen in many diseases and not exclusive for CD 
(Green et aJ . 2005) .  Marsh I I  lesion is characterized by crypt hyperplasia and lymphatic 
enteritis (Mulder & Cel lier, 2005). Marsh I I I  l esion is characterized by flat lesion contain 
intraepithel ial lymphocytosis, crypt hyperplasia and moderate to severe vi l lous atrophy 
(Abdul Karim & Murray 2003). 50- 60% of CD patients fal l  into this Marsh category 
(Green et aI . ,  2005). March 4 is characterized by i rreversible hypoplastic atrophic lesion in 
which malignant ( l ymphomatous) transformation can develop ( Mulder & Cell ier, 2005)  or 
total vi l lous atrophy (Abdul Karim & Murray, 2003). Normal biopsy never excludes an 
underl ing presence of latent DC (Green et aI . ,  2005 ). Vi l lous atrophy can be found in many 
diseases but positive serological tests are rarely found in those diseases as shown in figure 3 
(Abdul Karim & Murray, 2003) .  
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Figu re 1.3 : The different between normal intestinal vi l l i  and complete vi l lous 
atrophy in CD (Early, 2005)  
1 .2.8 Treatment  
The only treatment for CD is  the strict adherence to gluten free diet (GFD) food ( Freeman et 
a l .  , 2002; Early 2005;  Green et al ,2005), the word wheat free product is not necessari ly 
mean gluten free because gluten found also in  rye, and barley (Westerberg et aI . ,  2006). 
There is no threshold below which some GFD might be tolerated, according to the Codex 
Alimentarius Standard which is publ ished in 1 995 that defi ne GFD as food containing <0. 3  
0
0 protein  from gluten (Shepherd & Gibson, 2006). Many European and parts o f  USA 
fol low the Codex standard. Food Standard Austral ia  and New Zealand FSANZ have defined 
GFD as food that have no detectable gl uten and not contain oats and malt (Shepherd & 
Gibson, 2006). The best outcome for CD patients whether fol low Codex Standard or zero 
tolerated has not been resolved (Shepherd & Gibson, 2006). General ly no scientific data 
suggest what is amount of gluten that can be tolerated, thus, zero tolerance is recommended 
(Abdul Karim & M urray, 2003). Placing oats is sti l l  controversial some studies confirm that 
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oat I afe for most CD patients for period of up 6 months ( Freeman et al . ,  2002). 
ervele , there i s  no grantee that oat i s  not contaminated with wheat during manufacture. 
Therefore, oat should not be permitted unt i l  c l inically improvement occurs in GFD 
(Shepherd & Gib on, 2006). Improvement seen in the small  intestine biopsy with GFD has 
been documented in elderly patients with intestinal lymphoma (Freeman et aI . ,  2002). 
Muco al pathology hould be normal ized in response to GFG within 6- 1 2  months (Early, 
2005)  
Canadian Cel iac Association (CCA) has made survey on 268 1  of  the members to  eval uate 
the impact of GFD of their health (Zarkadas et aI . ,  2006); 83% of respondents report feel ing 
a lot better and reco ering from many symptoms that affect their l i fe and health (Zarkadas 
et aI . ,  2006). 
Upon the diagnosis of an individual as CD patients, physicians should immediately refer the 
patient to a dietic ian with expertise in CD. Qual ified dietician should provide al l  
restrictions, recommendations and guidel ines for patients (Mulder & Cel l ier, 2005 ). If the 
patient IS not responding to GFD after 6 months or longer and they may return to the 
symptoms such diarrhea, fatigue and weight loss, this case is named a refractory sprue; it i s  
a severe vi l lous atrophy which develop later to bowel lymphoma and other cancer (Early, 
2005). Patient should know that fol lowing a gluten free diet is not easy. GFD is more 
expensive and the food not tasty than food he used to eat. Patient should understand that the 
diet is long l i fe tenn (Westerberg et aI . ,  2006). Strict adherence to the GFD is the only 
protective effect against mal ignancy in adult (Freeman et aI . ,  2002). Canadian Celiac 
Association members identifies some difficulties related to GFD such avoiding travel and 
eating outside the home, finding GFD food with a good qual i ty, avoiding restaurants and 
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worrying about staying in hospital (Zarkadas et a i . ,  2006). Patients should be aware of 
hidden gluten product such a medication l ike itamins and mineral supplements, some kind 
of modIfied proces ed food, starch and vegetable gwn (Early, 2005).  It is necessary to 
upply pat ient with nutrients supplementation of i ron fol ic acid, and vitamins these 
supplementary hould be given to al l  elderly patients due to long duration of subcl i nical 
disease and the potential risk of mult i  deficiencies. Long term supplementations are not 
necessary once c l inical improvement has been achieved ( Freeman et a i . ,  2002). Others 
problems of GFD that cereal s  serve as primary grai n  food in most cereal based food these 
i nc lude bread, cookies, cake, pastries, pasta products, wheat is used as thick binder in many 
soup, sauces and dressing, sea food , sausage and used as coal ing on meat and fish 
(Zarkadas et ai . , 2006). There is no internat ional regulation in  the world requires food and 
drug companies to label products for gluten contents (Early, 2005 ). In 2004 Food Al lergen 
Label ing and Consumer Protection Act; based regulation that force companies to provide a 
c lear statement i f  the product contains the top 8 food al lergens includ ing wheat (Mulder & 
Cel l ier, 2005) .  
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I .  3 Objectives 
1 .  To find out the seropre alence of sub-cl inical and si lent cel iac disease among UAB 
adults in Al Ain. 
2. To find out the pre alence of CD cases among healthy UAE nationals adults based 
on smal l  bowel biops . 
3 .  To advise the volunteers with confirmed CD to  be  aware that they are diagnosed as 
ha ing Si lent or latent cel iac disease and should mention this to their doctors 
whene er the need for treatment arises in the future .  
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II. MATERIALS AND METHODS 
4 1  
I I . MATERIALS A N D  M E THODS 
I I . t  Subject and  M ethod 
I T .  1 .  I Study A rea 
Al Ain i the second largest city in  the Emirate of Abu Dhabi after the capital i tself 
located 1 60 km east of the capital, and approximately 1 40 km southeast of Dubai . 
I T . 1 .2 Study Design 
In  UAB, the prevalence ofeD is  not known though cases; both national s and expatriates, 
are diagnosed in hospitals. We hypothesized that cel iac disease remains under-diagnosed 
because of the wide spectrum of c l inical presentations that adults with cel iac disease can 
manifest i . e. the famous saying that we see the tip of an iceberg may wel l  apply to the 
disease condition in  UAB. lf the above is  true the need to perfonn a prevalence study among 
UAB nationals to find out the prevalence of cel iac disease and to raise the awareness of the 
medical practitioners and the general population against the disease becomes evident. 
This study is a cross-sectional seroprevalence study of CD among adult U AB 
nationals undergoing obl igatory prenuptial examination. A total number of 1 200 
subj ects were i nc luded. Al l  subjects were screened for both human tTG 19A and human 
tTG 19G. Seropositive subjects were tested for endomysium antibodies (EMA) and those 
positive were asked to volunteer for smal l  bowel biopsy to confirm serological results. A 
questionnaire was fi l led for each subject including personal information and questions on 
the general health status in  addition to basic demographical information. 
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n.1.3. Study Po pu lat ion and Blood a m pl ing:  
Blood was obtained from UAE nationals undergoing obl igatory premarital 
e. amination in Al Ain Hospita l .  A total of 1 200 subjects were sampled inc luding 574 
females and 626 males. The age of the subjects ranged from 1 5- 70 years. 
Blood sampling wa carried out between 23rd of September 2007 to 2nd of Apri l 2008. From 
each ubject, 5 ml of blood was obtained in plain tube and, sera were separated on the same 
da by Centrifugation for 1 0  min at 2500 rotations per minute (rpm) and stored at -800 C 
unti l used. For each subject a quest ionnaire was obtained including information on name, 
contact address, age, gender, education status, knowledge about CD, if previously diagnosed 
as CD patient, any diagnosis of CD in 1 st degree relatives, hi story of chronic diarrhea, 
anemia, headache, diabetes, tumor and thyroid anomaly. 
n.1.4 Ethica l Aspects 
Ethical clearance was obtained from the Research Review Committee at Tawam Hospital 
in July 2007. A written consent was signed by each subject agreeing to participate in the 
study after ful ly  explaining to hirnlher the objectives and the expected benefits of 
participating in it .  Healthy subjects with serological ly confirmed cel iac disease diagnosis 
were i nformed that they have a latent/si lent cel iac disease and were advised to reveal this 
i nformation to their physicians if  in  the future they complained from any symptoms. 
Moreover, an overview of tbe disease was given to every volunteer diagnosed as having a 
l atent/si lent cel iac disease in  order to make h irnlher fami l iar with the different facets of the 
disease (see appendices). 
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1 1 . 1 .5 erod iagnosis C riteria : 
A ample was tested for cel iac disea e according to the fol lowing flow chart (Fig. 2 .  1 )  
Figu re 2. 1 :  Flow chart for CD serodiagnosis. 
I Human tTG IgA I I Human tTG IgG I 
I I I J I I Positi e l I Negative I I Negative I Positive I 
I I No Celiac Disease 
End of tests 
I Total lgA I I 
I I I I gA normal }- I gA deficient I 
I I 
Anti-Endomysial Anti- Endomysial 
Antibody (EMA) 19A 
(EMA) Antibody IgG 
I I 
I I I Negative I I Negative I I Positive I Positive I 
I I 
Serology Positive for Undetermined CD 
eel  iae di sease serological status 
No cel iac Disease 
end of the tests 
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Final ly, a l l  erology po it i e subjects were asked to undergo upper gastrointestinal 
endo copie . In this tud the fol lowing cri teria wi l l  be used to identify subjects as hayjng 
confinned CD if bIOp shO\ ed Marsh 1 , 2 or 3 type lesions with positive serology. 
I I . 2 .  M ethods 
1 1 .2. 1 Tissue transgl u ta m i nase tTG- IgA a n d  IgG 
tTG 19A and tTG IgG ELISA was measured using k its based on human recombinant 
transgl utaminase ( IBL Diagnosis  Company, Gennany). The test is based on sol id phase 
enzyme l i nked immunosorbent assay (ELI SA). The wel l s  were coated with antigen; specific 
antibodies if present in the sample bound to the antigen coated wel ls were detected by 
secondary enzyme conj ugated antibody (E-Ab) specific for 19A or IgG. After the substrate 
reaction the i ntensity of the color developed was proportional to the amount of 19A or IgG 
specific antibodies detected. Results can be detennined directly by using the standard curve 
as quantitative or qualitative the optical density the positive controls to 0.2 1 for tTG 19A 
and 0.3 1 for tTG IgG . Each kit contains the fol lowing 6 cal ibrators A, B, C, D, E, F as 
standards and their concentrations were 0 . 1 ,  1 ,  3, 1 0, 30, 1 00 U/ml,  receptively of 19A 
antibodies against transgl utaminase in  TBS buffer and preservative. Positive control 
contained 19A antibodies against t issue transglutaminase in TBS buffer and preservative and 
negative control in TBS buffer and preservation. Enzyme conj ugate contained anti human 
19A conj ugated to peroxidase in buffer and preservative, TMB substrate solution contained 
TMB and hydrogen peroxide. M icrotiter plate wel ls  were coated with human recombinant 
tissue transglutaminase, sample di l uents contained TBS and preservative, wash buffer 
concentration l Ox in  TBS and preservatives and stop solution 0 .5  M H2S04. For tissue 
45 
transgl utamina e IgG kit components were the same a the IgA kit except for the enzyme 
conjugate that contained anti human IgG peroxidase in buffer and preservative. 
On the arne day of anal sis al l sera were thawed at room temperature. tTG kits were taken 
out ide the fridge to reach room temperature. Wash buffer was prepared by adding 1 00 ml  
of di lute to  1 l iter of  disti l led water. Samples were di luted by adding 5 11 1  of  sample to  500 II I 
of ample d i luents reagent. Wel ls coated with antigen were fi l led with 300 III of wash buffer 
each, and soaked for about 1 0  seconds and then decanted. 1 00 II I of Calibrators, controls 
and dil uted samples were pipette into the respective wel l s  and incubated for 30 min at room 
temperature. After the incubation the plate was washed manual ly 3 times with 300 II I of 
\ ash buffer; excess solution was removed by tapping the inverted plate on a paper towe l .  
1 00 III anti-human 19A or  IgG peroxidase conjugated antibodies 19A or  IgG to  peroxidase in  
buffer and added into each wel l .  Then the plate was incubated for 30 min at room 
temperature. I ncubation solution was discarded and the plate washed as mentioned above. 
1 00 III of substrate containing TMB and hydrogen peroxide was added to each wel l  and the 
plate incubated for 30 min at room temperature in the dark. 1 00 II I per wel l  of stop solution 
was added and the plate tapped gently to mix the contents . Optical density was measured 
\.vi th photometer at 450nrn (Reference-wavelength: 600-650 nm) within 30 mints after 
adding the stop solution. 
According to the tTG IgA and I gG kits one of each negative and posi tive control and 
cal ibrators control should be tested along every sample batch. Controls and calibrator 
should be within acceptable ranges which for tTG IgA were as fol lows (Table 2 . 1 ), whereas, 
the acceptable ranges for tTG- I gG were as fol lows (Table 2 .2 )  
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Table 2.1: The acceptable range of tTG IgA calibrators and controls expressed as OD and 
U/m! . 
Calibrators Result OD Acceptable range OD 
Calibrator A 0 05 2  < O. 1 00 
Calibrator F 2 3 78 > 1 000 
Controls Result Vlm l Acceptable range Vlml 
Po itive control 25 2 1  - 30 
Negative control 0 . 4 1  < 2 . 5  
Table 2.2: The acceptable range of tTG I gG cal ibrators and controls expressed as OD and 
U/m! .  
Calibrators Result  on Acceptable range on 
Calibrator A 0.049 < O.  1 00 
Calibrator F 2 . 3 73 > 1 . 000 
Controls Resul t  Vlml Acceptable range 
VIm I 
Positive control 2 5  23 - 3 2  
Negative control 0 77 < 2 . 5  
The test was considered inval id when the results of controls fal l  outside the acceptable 
range. I n  th is  study the results can be expressed qual i tatively, the OD of the samples was 
compared with the Borderl ine OD. The latter was determined according to the fol lowing 
formula absorbance OD was determined according to the fol lowing formula :  
OD borderline = OD positive control X factor 
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The factor depend on kit lot which was in this kit for IgA = 0.2 1 ,  whi le for IgG was = 0.3 1 .  
Then one can find the ratio of the sample by using the formula: 
RatIO = OD . ample I OD borderlllle. 
Interpret ing the result for tTG IgA and for tTG IgG was based on cutoff val ues as fol lows: 
cutoff for the posit i  e, equi ocal and negative cases using qual itative eval uation ratio for 
tTG 19A > 1 .2 ,  0 .85 - 1 . 2 and <0.85 ,  respectively. Cutoff for the positive, equivocal and 
negative ca es using qualitat ive evaluation ratio for tTG I gG > 1 . 1 5 , 0.9- 1 . 1 5  and <0.9, 
re pecti ely. 
ll .2 .2 Tota l H u m a n  Seru m IgA 
Quantitative detennination of human IgA in  serum was done by sandwich ELISA. The test 
was carried out according to the i nstruction of the kit manufacturer (XEMA- Medica, 
Russia). IgA from the samples was captured by the antibodies coated onto the microwel ls  
surface unbound material was removed by washing. Second antibody directed against 
another epitopes of IgA and labeled with peroxidase enzyme was then added into the 
microwel ls. After subsequent washi ng procedure, the enzymatic  activity bound to 
microwel ls  surface was detected and quantified by addition of the substrate mixture. Then 
the stop solution was added and the optical density was measured at 450 nm; which is 
directly related to the quanti ty of the measured I gA in the samples. 
The kit contained cal ibrators with concentrations of 0, 0 . 1 ,  0 .5 ,  2, 5 gil, control ,  sample 
di luents E IA buffer, EIA buffer to be added to microwel l  prior to addition of dil uted 
samples, enzyme conj ugate, substrate solution containing TMB, twelve separate strips of 
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eight e l l  coated with pecific antigen, wash sol ution concentrate 1 0  amount contain PBS 
buffer, top sol ution 0.5 H,S04 and a plate seal ing tape. 
Thl te t wa done onl for the reacti e and borderl ine tTG IgG samples with negative tTG 
IgA result to explore whether such di crepancy could be explained by deficiency in the 
total IgA 5 11 1  of ample was d i luted with 995 II I of EIA di l ution buffer. The desired 
numbers of microstrip were arranged into the frame, and then cal ibrators, control samples 
and samples in dupl icates were added to the wel l s  (controls  and cal ibrators added without 
di l ution). 1 20 III of red EIA buffer was pipette into unknown sample wel l .  1 00 III of 
calibrator and controls were added into al located wel ls. Then 5 II I of di luted samples were 
added into al located wel l s. The addition was made within 3 minutes to ensure a uniform 
incubation t ime for al l  samples. Contents of the wel l s  were mixed by short horizontal 
rotating of plate for 5 -7 seconds; plate was covered by plate adhesive tape and incubated for 
30 minutes at 3 7°C. Wash buffer was prepared by adding 1 20 ml  of disti l led water to 1 2  ml  
of washing solution l O X then the plate was washed 3 times. 1 00 II I  of conjugate was 
dispensed i nto the wel l s  then plate was incubated for 30 minutes at 3 7°C. Plate was washed 
5 times then 1 00 III of substrate was dispensed into the each wel l s. Plate was incubated for 
1 0-20 minutes at 20-25°C. 1 00 II I  of stop solution was pipette into the wel ls. Optical density 
was measured at 450 nm. 
The data obtained quantitativel y  evaluated with a standard curve drawn by hand on l inear 
graph paper. The concentrations of the 5 cal ibrators were 0 .0, 0. 1 ,  0 . 5 ,  2 and5 gil. OD 
values of the cal ibrators (y-axis) were plotted against their concentration s (x-axis). 
Concentrations of the samples can be read directly from the standard curve. 
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The test wa considered " al id when the concentration of control sample was in the range 
between 0. 5-2 gil and the concentration of the cal ibrator 5 is not less than 1 . 5 gil .  Reading 
of the sample wa obtained quantitatively from the standard curve. 
1 1 .2.3 Ao ti-Eodomy ia l  Ant ibody ( E MA )  
Done by u ing a kit based o n  indirect immumofluorescence antibody test for qual itative and 
emi-quantitative assessment of endomysial antibodies; manufactured by ( I MMCO 
diagnostics, Buffalo, USA). Patients sera were incubated on tissue section to al low binding 
of antibodies to the sub trate. Any antibodies not bound are removed by rinsing. Bound 
antibodies of the IgA or I gG class were detected by incubation of the substrate with 
fluorescein-labeled, anti-human immunoglobulin conj ugate. The tests were examined under 
a fluorescence microscope equipped with appropriate fi l ters Axiovoision 3 . 1 ,  Zeiss 
Axcocam camera, Zeiss Co. Germany). The presence of EMA was demonstrated by an 
apple green fluorescence of the endomysi um l ining of smooth muscle bundles. 
Each kit contained 8 sl ides each with 6 wel l s  coated by primate smooth muscle, s l ides' 
substrate, EMA positive control human serum, EMA negative control human serum, anti­
human IgA FITC conjugate with Evan 's  b lue counterstain, sample di l uents buffer, 
phosphate buffered sal ine PBS, mounting medium and cover-sl ips. 
The test was done only for positive samples in tTG IgA and tTG IgG. On the same day of 
analysis all sera and reagents were placed at room temperature. Buffer di luents was ready to 
use, whereas, phosphate buffered sal ine PBS was di ssolved in 1 l iter of disti l led water. 
Patient serums were di luted by adding 200 �.d of serum to 300,.d of buffer di luents 1 :2 . 5 .  
Controls were used undi l uted. S l ides were removed careful ly without touching the substrate 
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and were labeled and placed in incubation chamber l i ned with paper towels moistened with 
\ ater to prevent dryI ng. 50!!1 of negative control was appl ied to wel l  number 1 and 50 II I of 
po I tive control to wel l  number 2. Then 5011 1  of di luted samples were appl ied to other 
\ e l l s .  Lid wa placed on incubation chamber and the slide was incubated for 30 minutes at 
room temperature. l ide \ as remo ed from the incubation chamber, and then was rinsed in 
beaker fi l led with PBS and then transferred immediately into Copl in jar and washed for 1 0  
minutes. hde \ as removed from Copl in  jar then the edge of the s lide was blotted on a 
paper towel to remove excess PBS. Shde was placed in incubation chamber then the 
conj ugate dropper ial was gently squeezed to apply 1 drop to each wel l .  Lid was replaced 
on incubation chamber and incubated for 30 minutes at room temperature. Sl ide was 
removed from the incubation chamber and then s rinsed in beaker fi l led with PBS and was 
dipped in a beaker containing PBS to remove excess conjugate. S l ide was transferred 
immediately into Copl in jar and was washed for 1 0  minutes. The excess PBS was removed 
by blotting as explained above. Whi le  the s l ide sti l l  wet coversl ip was mounted by adding 3 
drops of the mounting medium evenly spaced on covers l ip and inverting the s l ide onto the 
coversl ip. To remove any air bubble  a gentle pressure was applied along the edge of the 
coversl ip. Same steps were repeated for each sl ide. S l ides were examined by fluorescent 
microscope at a magnification of 200X or greater. Negative in both IgA and IgG tests was 
considered as free from cel iac, whi le positive samples would consider as serological ly  
positive cel iac disease and the patient was asked to  do endoscopy. 
Both negative and positive control s  were included with each test run. Negative control 
should show no specific fluorescence of the endomysi um l i ning of the smooth muscle 
bundles, whereas the positive control should give 2+ or greater staining intensity of the 
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tubule of mooth mu c1e bundles. The te t should be repeated when the controls did not 
behave as expected. 
The po iti e result of the tests for endomysial antibodies obtained qual itative through the 
mtenslty of the tubules of smooth muscle  bundles. Were + referred to low intensity, + + 
referred to middle intensity and +++ referred to high intensity Endomysial antibodies react 
as network of the thin, irregular l ines around the sarcolemma of the individual smooth 
muscle  fibn ls  (figure 2 .2 ). 
Figu re 2.2: EMA staining reaction on primate smooth muscle, 200x staining of l ining 
of the smooth muscle  bundles. 
n.3 Statistical  Ana lyses 
Data were analyzed on personal computer using SPSS (version 1 5 .0, SPSS Inc . ,  Chicago, 
I L). The l inear by l i near, the Pearson chi-square test and the Fisher exact test were used to 
compare variables between females and males. The relationship between the variables as 





I I I .  RESULTS 
I I I . 1 .  ubject characteristics 
ubJect were UAE national adult males (n = 626) and females (n  = 574) who came to AI Ain 
Ho pital for premarital test Col lection of blood amples was carried out from September 
2007 to Apri l 2008. A total of 1 430 subjects were asked to participate in the study and 1 2 1 1 
( 84 .70 0) agreed. Out of tho e included, 1 1  blood samples were excl uded because of been 
gro sl hemolytic .  Therefore, a total of 1 200 UAE national subjects were included in the 
study. Sample size wa calculated on the basis of 2005 AI Ain population census with 
estlmated prevalence of CD of 1 .0% and a confidence level of 95% and an estimated 
confidence interval of 0 . 5 8 . The estimated sample number was 1 1 50 and it was adjusted to 
1 200 to inc lude about 40 0 more than the required number. 
m .2.  Demograp h ic data 
The age range of the participants was 1 6-70 years with a mean ± (S .D . )  of 24. 87 ± (6. 35 ). The 
distribution of subjects into 6 age groups according to gender showed that the majority 
(87 .4%) was between 1 6  and 30 years and there were more males than females except in the 
1 6-20 years age group ( Fig. 3 . 1 ). 
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Figu re 3.1: Di tribution of UAE nationals according to age. 





The distribution of subjects according to education i l l ustrates that the proportion of females 
\ ho finished university education was higher compared to males (Fig. 3 .2) .  
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Figu re 3.2: Distribution of UAE nationals according to educational status. 
i l l iterate Read and Primary Preparatory Secondary University Graduate write Studies 




The distributions of age and education were significantly different between females and males 
[(x2 = 7 1 . 739 ; P < 0.00 1 and xJ = 74. 787; p < 0.00 1 ,  respectively) (Table 3 . 1 . )] .  
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Table 3.1 : Distribution of age and educatlOn according to gender among sampled 
subjects. 
Demogra phic Freq uency (%)  p 
Cha racteristic Total  Ma les Fema les 
Age 
/ 1 6 - 20 247 (20.6) 73 (29.6) 1 74 (70.4) 
2 1  - 25 546 (45 . 5 )  29 1 (53 . 3 )  255  (46. 7) 
26 - 30 256 (2 l . 3 )  1 59 (63 .6)  97 (36 .4)  7 l . 739 < 0 .00 1 
3 1  - 3 5  96 (8 .0)  56 ( 58 . 3 )  40  (4 l . 7) 
36 - 40 22 ( 1 . 8 )  1 5  (68 .2)  7 (3 1 . 8) 
Above 40 33 (2 .8 )  32 (97.0) 1 (3 .0 )  
Ed ucation 
I l l iterate or 
Read and write 1 3  ( 1 . 1 )  1 3  ( 1 00.0) 0 (0.0) 
Primary 4 1  (3 .4)  36 (87 .8 )  5 ( 1 2 . 2 )  
Preparatory 1 52 ( 1 2 . 7) 1 08 ( 7 1 . 1 )  44 (28 .9) 74 . 787 < 0.00 1 
Secondary 490 (40. 8 )  265 (54. 1 )  225 (45 .9)  
University 489 (40 .8 )  1 93 (39. 5 )  296 (60. 5 )  
graduate studies 1 5  ( 1 . 2 )  1 1  (73 . 3 )  4 (26.7) 
* x'" alue i s  for l inear-by- l inear association. 
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III. 3 Question na ire Data 
All  ubJects \ ere mqUired about the following : cel iac awareness, self or first degree relative 
prevlOusl diagno ed as CD, history of anemia, chronic headache, chromc diarrhea, diabetes, 
tumor, th roid anomaly and hepatit is .  Since, none of the subjects was previously diagnosed as 
CD patient therefore; the ariable pre iously diagnosed as CD patient, was not inc luded in 
data analysIs any further. 
III. 4 Serologica l  Resu lts 
Fourteen ubjects ( 1 .2%) were positive for tTG 19A and EMA IgA, whereas the remained 
1 1 86 (98 .60 0) subjects were clear cut negatives for tTG IgA. Five of the above mentioned 1 4  
subjects were also positive for tTG IgG, and only 4 of them were also positive for EMA IgG. 
One subject was equivocal on tTG IgG and positive in  EMA IgG. The remaining 8 subjects 
were negative in tTG I gG and only 5 of them were positive for EMA IgG. 
Of the 1 1 86 tTG IgA negative subjects two were positive for tTG IgG and 2 were equivocal .  
Out of the two posit ives, one was negative i n  the two EMA tests and therefore was considered 
as a CD free subject. The other positive subject was also positive for EMA IgG and negative 
for EMA 1 9A.  He was excluded from the data analysis because the cel iac status could not be 
determined serological ly .  One of the two equivocal subjects in tTG IgG was positive for EMA 
IgG and negative for EMA IgA, whereas the other one showed the opposite pattern with 
regard to EMA i .e .  negative for EMA I gG and posit ive for EMA IgA. Both subjects were also 
excluded from the data analysis for the same reason as the aforementioned excluded subject. 
Anemia  was the most common cl in ically associated parameter in CD positive subjects (Table 
3 . 2) .  
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Table 3.2: Anti tTG EMA I gA and I gG antibodies in :  1 4  positi e subjects 
(serological ly CD si lent or latent); one negative (serological ly CD free) and 3 
e cI uded ubject on the ba is of undetermined CD serological status. 
tTG IgAt tTG IgGl 
Overa l l  u bject Gender Age q ua l ita tive q ua l itative E MA  E MA  CD" C l i n ical
li 




1 M 24 7.6 0. 1 87 + + +  + 1 a 
2 F 2 8  1 . 27 0 .2 1 4  + + + +  t 
3 F 22 2 .42 0.490 + + +  -ve n 
4 F 24 3 .6  1 . 39 + +  -ve 1 n 
5 F 23 8 .25 2 . 2  + + +  + +  1 a 
6 F 20 3 . 1 5  0 .75 + +  -ve 1 n 
7 F 20 6 .6 0. 5 1 3  + + + -ve n 
8 F 22 4 . 87 0 .9 1 4  + + +  + +  1 a 
9 F 25 9. 1 0. 1 89 + + +  + +  1 n 
10 F 1 8  9 . 89 1 . 53  + + + +  a 
11 F 24 9. 1 3  0. 347 + + +  + +  1 n 
12 F 27 7.6 0.269 + + + +  1 n 
13 F 24 4 .25  1 . 77 + + + +  1 n 
14 F 22  6.78 4 + +  + a 
15 M 23 0.60 1 . 04 -ve + + +  3 n 
16 F 2 8  0 . 5 0  1 . 249 -ve -ve 2 n 
17 F 27 0 .76 1 . 09 + -ve 3 n 
18 M 25 0 .409 1 . 2 8  -ve + + +  3 n 
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tCutoff for the po it ive, equi oca) and negati e ca es using qualitative evaluation ratio for 
tTG IgA > 1 .2 ,  0 . 85 - 1 . 2  and <0. 85 re pecli ely. 
tCutoff for the po iti e, equi ocal and negative cases using qual i tative evaluation ratio for 
tTG IgG > 1 . 1 5 , 0 .9- 1 . 1 5  and <0.9 respectively . 
• 1 = posit) e, 2 = negati e and 3 = undetennined and excluded from further analysis. 
/! a = anemia t = thyroid anomal and n = no complain. 
I n . 5 Assoc iation of gender  a n d  other va riables w ith CD serology 
In order to test for any association between gender and variables observed through 
que tionnaire on one hand and CD serology on the other results of s imple logistic regression 
analyses are presented in Table  3 . 3 .  Only cel iac awareness anemia, thyroid anomaly and 
gender were significantly associated with CD serology. The crude OR (95% CI)  of females 
being seropositi e for CD serology compared to males was [ 1 4 .462 ( 1 . 886- 1 1 0 .909), p < 
0 .00 1 ] . 
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Table 3.3 : Result of simple lOgIstic regre sion anal ses of CD serology versus gender and 
anamenistic ariab1es obtained through questionnaire. 
Pa ra meter CD Serology 
Freq uency 
OR (95% C I )  
pb 
n ( % )  negative posi tive 
n ( % )  n ( % )  
eliac Awareness 
a 1 1 83 (98. 8)  1 1 7 1  (99 .0)  1 2  ( 85 . 7) 0 
< 0.009 
es 1 4 ( 1 . 2 )  1 2  ( 1 . 0) 2 ( 1 4. 3 )  1 6. 264 ( 3 .279-80.663) 
C D  in 1 st degree 
family member 
O B 1 1 95 (99 . 8)  1 1 8 1  (99 .8 )  1 4  ( 1 00)  
0 .828 
Yes 2 (0. 2 )  2 (0 .2 )  0 .0  (0.0) 
Anemia 
No B 1 1 06 (92 .4)  1 097 (92 . 7) 9 (64 .3 )  
<0.003 
Yes 9 1  (7 .6)  86 (7 .3 )  5 ( 35 . 7) 7 .087(2 .324-2 1 .6 1 2 ) 
Headache 
No B 1 1 85 (99 .0)  1 1 7 1  (99 .0)  1 4  ( 1 00)  
0 . 594 
Yes 1 2  ( 1 .0 )  1 2  ( 1 . 0) 0 .0 (0.0) 
Chronic Diarrhea 
No a 1 1 92 (99.6) 1 1 78 (99.6) 1 4  ( 1 00)  
0 .73 1 
Yes 5 (0 .4)  5 (0 .4)  0 (0.0) 
Diabetes 
No B 1 1 76 (98 .2)  1 1 62 (98.2 )  1 4  ( 1 00)  
0 .480 
Yes 2 1  ( 1 . 8) 2 1  ( 1 . 7)  0 (0 .0)  
6 1  
Tumor 
No 8 1 1 96 (99.9) 1 1 82 (99.9) 14 ( 1 00) 
0. 878 
Ye 1 (0. 1 )  1 (0. 1 )  0 (0 .0)  
Thyroid 
No n 1 1 88 (99.2 )  1 1 75 (99 .3 )  13  (92.9) 
<0.09 
Yes 9 (0 .8)  8 (0 .7)  1 (7. 1 )  1 1 . 298 ( 1 . 3 1 7-96.945)  
Hepatitis 
No 8 1 1 86 (99. 1 )  1 1 72 (99. 1 )  1 4 ( 1 00)  
0 .6 1 0  
Yes 1 1  (0 .9) 1 1  (0 .9) 0 (0.0) 0.000 (0 .000-0.000) 
Gender 
male 8 624(52 . 1 )  623 (52 .7) 1 (7 . 1 )  
<0.000 
female 5 73 (47.9) 560 (47.3 )  1 3  (92.9) 1 4 . 462 ( 1 . 886- 1 1 0 .909) 
a Reference group 
b Omnibus tests of Model Coefficients 
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Table 3.4: Adjusted OR and 95% confidence intervals for celiac disease antibodies in UAE 
nationals from Al Ain. 
Pa ra meter OR (95% C I )b P 
Celiac Awarene s 
No 1 8  
0.007 
Yes 1 0 . 289 ( 1 . 897 - 5 5 . 802) 
Anemia 
No 1 8  
0.01 
Ye 4. 577 ( 1 .447 - 1 4 .476) 
Gender 
male 1 8  
0.026 
female 1 0 .465 ( 1 . 333  - 82. 1 43 )  
a Reference group 
b OR adjusted for cel iac awareness, history of anemia, history of thyroid anomaly and gender. 
The adj usted OR using multiple l ogistic regression for the statistical ly significant parameters 
in binary logistic regression re ealed that only cel iac awareness, anemia and gender were 
independently associated with CD serology. For gender, the adjusted OR (95% CI)  was 
[ 1 0 . 465 ( 1 . 333- 82 . 1 43), p < 0 .03]  as presented in Table 3 .4 .  The odds of CD seropositive 
among females are 1 0. 465 times higher than among males. The odds of CD seropositive 
among those with awareness of the diseases are 1 0 . 289 times higher than among those 
\vithout awareness. Moreover, the odds of CD seropositive among those with anemia are 
4 . 5 77 times higher than among those without anemia. 
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In  addition to the difference In CD serology X2 = 9 .737, P <0.003 males and females UAE 
were al 0 igni ficantl di fferent in cel iac awarene s, hi tory of anemia and diabetes as 
pre ented in Table 3 . 5 .  
Table 3.5: Distribution of  CD serological results and questionnaire data i n  adult male and 
female UAE nationals in Al Ain. 
Parameter Freq uency M a le Female 
l p 
n ( % )  n ( % )  n ( % )  
C D  Serology 
egative 1 1 83 (98. 8)  623 (99 .8) 560 (97. 7) 
9 .737 <0.003 
Positive 1 4  ( 1 . 2 )  1 (0 .2 )  1 3  (2 . 3 )  
Celiac Awareness 
0 1 1 83 (98 .8)  62 1 (99 .5 )  562  (98 . 1 )  
4 . 1 78 < 0.05 
yes 1 4  ( 1 . 2 )  3 (0 . 5 )  1 1  ( 1 . 9)  
C D  in 1 st degree 
family member 
No 1 1 95 (99 . 8)  624 ( 1 00)  5 7 1  (99.7)  
0 .229* 
Yes 2 (0 .2)  0 (0 .0) 2 (0.3 )  
Anemia 
No 1 1 06 (92.4) 60 1 (96 . 3 )  5 0 5  ( 88. 1 )  
27.3 1 1  <0.001 
Yes 9 1  (7 .6)  23 (3 .7) 68 ( 1 1 . 9)  
Headache 
No 1 1 85 (99 .0)  6 1 8  (99.0) 567 (99 .0)  0 .000 1 .000 
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Yes 1 2  ( 1 . 0)  6 ( 1 .0)  6 ( l .0)  
h ronic Diarrhea 
No 1 1 92 (99.6) 62 ] (99. 5 )  5 7 1  (99 .7) 
1 .0*  
Yes 5 (4 .4)  3 (0 . 5 )  2 (0.3 )  
Diabete 
No ] 1 76 (98 .2)  606 (97. 1 )  570 (99 . 5 )  
8 .34 <0.005 
Yes 2 1  ( 1 . 8) 1 8 (2 .9)  3 (0.5 )  
Tumor 
No 1 1 96 (99.9) 623(99 .8)  5 73 ( l 00)  
1 .0 *  
Yes 1 (0 . 1 )  1 (0 .2)  0 (0 .0)  
Thyroid 
No 1 1 88 (99.2 )  622(99.7)  566(98 .8 )  
0 .096* 
Yes 9 (0. 8) 2 (0 .3 )  7 ( 1 . 2 )  
Hepatitis 
No 1 1 86 (99. 1 )  6 1 7  (98 .9)  569 (99 .3 )  
0 .2 1 6  0 .642 
Yes 1 1  (0 .9)  7 ( 1 . 1 )  4 (0 .7) 
* F isher's Exact Test 
The above gender differences make it plausible to test the association of questionnaire data 
with CD serology in females as they constitute the bulk of CD positive cases ( 1 3  out of 1 4). 
Binary logistic regression was used to test which of the questionnaire parameters associates 
with the CD serological results i n  females. Only CD awareness and history of anemia were 
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found to a OClate WIth antI tTG and anti EMA IgA antibodies i .e .  posit ive serology, as shown 
in Table 3 6. 
Table 3.6: Re ults of sImple logistic regression analyses of CD serology versus anamenistic 
vanables obtained through questionnaire in female subjects. 
Pa ra meter CD Serology 
Frequency negative positive OD (955% C I )  pb 
n ( % )  n ( % )  n ( % )  
Celiac Awareness 
a 562 (97.7) 55 1 (98 .0)  1 1  ( 8 1 . 8) 0 
0.02 
yes 1 1  (2 .3 ) 9 (2 .0)  2 ( 1 8 .2)  1 1 . 1 3 1  (2 . 1 5-57.632) 
CD in 1 s f  degree 
family member 
No s 5 7 1 (99 .7)  558  (99.6) 1 3  ( l 00 .0)  
0. 762 
Yes 2 (0.3 )  2 (0 .4)  0 (0 .0)  
Anemia 
0 8 505 (88. 1 )  496 (88 .6)  9 (69 .2)  
0.066 
Yes 68 ( 1 1 . 9)  64 ( 1 1 . 4 )  4 (30 . 8 )  3 .444 ( 1 . 03 1 - 1 1 . 507) 
eadache 
N0 8 567 (99.0) 554 (98.9) 1 3  ( l 00.0) 
0. 599 
Yes 6 ( 1 .0 )  6 ( 1 . 1 )  0 (0 .0)  
hrooic Diarrhea 
No a 5 7 1 (99 .7)  558  (99 .6)  1 3  ( l 00 .0) 0 .762 
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Yes 2 (0.3 )  2 (0 .4)  0 (0 .0)  
Diabete 
No a 5 70 (99 . 5 )  557  (99.5 )  1 3  ( 1 00 .0) 
0 .7 1 0  
Yes 3 (0. 5 )  3 (0. 5 )  0 (0.0) 
Thyroid 
N0 8 566 (98 .8)  554 (98 .9)  1 2  (92 . 3 )  
0. 1 4 1  
Yes 7 ( 1 . 2 )  6 ( 1 . 1 )  1 (7 .7) 7.694 (0 .859 - 68 .95)  
Hepatitis 
No o 569 (99 . 3 )  558  (99 .3 )  1 3  ( 1 00.0) 
0 .668 
Yes -l (0 .7)  4 (0 .7)  0 (0 .0)  
a Reference group 
b Omnibus tests of Model Coefficient 
The adjusted OR and 95% CI for cel iac antibodies in  relation to cel iac awareness and hi story 
of anemia are presented i n  Table 3 .7 .  Both parameters were independently associated with CD 
serology though the association for h istory of anemia approach statistical s ign ificance OR 
(950 0 CI)  was 3 . 3 1 8(0.969 - 1 1 . 359);  P = 0.056 
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Table 3.7:  dJ u ted R and 950 0 confidence Interval for c hac dl ea e antibodIes in female 
subjects 







OD (99% C I )b 
1 0 . 565 ( 1 .972 - 56. 6 1 5 ) 
3 . 3 1 8(0.969 - 1 1 . 359) 




In  female ubj ect , the odd of CD seropositi e among those with awareness of the diseases 
are 1 0. 565 t imes lugher than among those without awareness. Final ly, the odds of CD 






The epidemiological pattern of CD in  the world has changed due to many factors e.g., more 
awar ne of the different c l in ical pre entation of CD and disco ering of new serological tests 
whi h are simpler and inexpensi e led to increase in the power of detecting many previously 
undiagnosed CD patients (Accomando & Cataldo, 2004). Before the new serological test the 
prevalence of CD was low and it was thought to affect only Europeans or their descendants 
(Accomando & Cataldo, 2004). With the help of new methods the prevalence increased and it 
reaches in some countries 1 :  1 33 (Niewinski, 2008), in spite of these efforts to detect CD, the 
true prevalence is sti l l  not c lear. 
Some prevalence studies detect the disease in blood donors such in Iran (Shahbazkhni et aI . ,  
2003), Tunisia (Mankai et aI . , 2006) and Brazi l  (Gandolfi  et aI . ,  2000) .  Study o f  blood donor 
population has many i nherent disad antages; blood donor prevalence does not reflect the real 
prevalence of the general population because most of the donors are males, whi le  many 
studies indicate higher prevalence of CD among females. Moreover, anemic subjects are 
excl uded and hence exc lusion of many CD patients as anemia i s  one of the most important 
signs of the disease (Accomando & Cataldo, 2004). In Middle East there are few studies on 
the pre alence of CD among general population, most of the studies focused on high risk 
population such as those having autoi mmune disease e .g. diabetes mel l itus type I and 
autoimmune thyroiditis (Rostami et aI . ,  2004). Some studies in the Middle Ease based on 
diagnosis cases and i ts retrospect ive data didn't inc lude a large number of population 
(Accomando & Cataldo 2004). To our knowledge there are no publ i shed studies on CD in the 
United Arab Emirates and therefore most probably this is the first CD prevalence study in  
UAE .  This study is a cross sectional seroprevalence of  CD among adult UAE nationals 
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undergoing obl Igatory prenuptial exami nation. The prenuptial tests inc lude screening for HIV, 
hepatitis B, syphi l i s  and anemia profi le .  The target population is only adolescence and adult 
males and female who seem healthy at time of sam pIing. Choosing of this group of subjects 
was adequate as the aim of the study is to detect s i lent/latent CD in adults UAE nationals; and 
tho e healthy subjects came to the test center to give blood for the above mentioned prenuptial 
tests and therefore no need for much formidable effort to persuade them to participate in the 
tudy. Moreo er, it is  more l i ke ly to give balanced sex ratio than selecting the subjects from 
blood donors. The s l ightly more proportion of males in our study can be explained by the fact 
that females denied more frequently to part ic ipate in the study compared to males (data not 
shown). Moreo er, some males came alone as they intended to marry foreigners and the 
prenuptial tests for non UAE nationals is  not carried at the test center at AI Ain Hospital but 
rather in the Preventive Medicine Department. 
The serological testing of the study on general population is based on many studies and 
criteria of diagnosis of CD. The American Gastroenterological Association AGA requires to 
carryout serological tests of CD before doing the endoscopy (Rostom et a I . ,  2006). The first 
level of serological tests for d iagnosis of CD i s  screening for anti- gl iadins I gA and IgG. The 
second Ie e l  of serological test is screening positive samples with EMA IgA then undergoing 
endoscopy. Total 19A serum i s  required to detect IgA deficiency and for positive samples i n  
I gG then those samples have t o  b e  screened for EMA IgG and final ly endoscopy (Gomez et 
al . ,  200 1 ). Many studies used t issue trans glutaminase IgA and I gG i nstead of anti gl iadins 
which i s  l ess sensitive and specific than tTG (Tatar et aI . ,  2004). There are controversies of 
using I gG i nstead of total serum 19A to detect I gA deficiency; many studies indicate the 
usefulness of using tTG IgG and EMA IgG in detecting CD i n  patients having IgA deficiency 
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(Cataldo et aI . ,  2000; Kumar et aI, 2002 ; Dahlbom et aI . ,  2005). According to Rostom et al . ,  
(2002), the sensiti i o f  tTG I gG and EMA IgG is c lose to 1 00% in IgA deficient patients, in  
addition mea uring total serum IgA along wjth the tTG- 19A or  EMA IgA as  first steps is 
preferred " hen IgA deficiency is strongly suspected, however, patients wjth diabetes mell i tus 
type I expre IgG 1 isotype wjth normal IgA level which may explain the positive tTG and 
EMA 19G and normal IgA total in some cases (picare l l i  et aI . ,  2005 ). In this study 1 4  ( 1 . 2%) 
of the subject were positive in tTO 19A and EMA IgA which i l l ustrate the correlation 
between the results of tTG IgA and EMA IgA. 5 subjects of the 1 4  were also positive for tTG 
19O, onl 4 of them were also positive for EMA 1 9O. According to Dahlbom et ai . , (2005 ) 
the majority of IgA sufficient patients are positive for 19A concurrently had elevated IgG in  
both tTG and EMA and this may be  due to  methodological l imi tation or  immunological 
d ifference in the i sotype response . IgA tTG seems to be directed mainly against 
conformational tTO epitopes and it may that IgO is directed against the same epitopes. Hence 
a competition between tTG I gA and 19G might take place and this competition would favor 
antibodies wjth high avidity for tTG ( Dahlbom et at , 2005 ). 3 subjects were exclude from the 
positive result because one samples was negative in tTG IgA, doubtful in tTG-IgO but had 
week positive in EMA- 1 9A and negative i n  EMA- IgO and negative in total 19A and 2 
subjects were negative i n  both tTG- 19A and EMA- I gA but positive in  tTG- 19G and EMA­
IgG and they have normal level of total 19A, since th is  study rely  on IgA serology and only on 
I gG i n  case of total IgA deficiency. However, one study ident ified new cel iac subgroup that 
positi e for IgG in tTO and EMA and negative in IgA in tTG and EMA and could be 
explained by a different i sotypic switch leading to development of B-ce l l  c lones, produci ng 
IgG 1 i nstead of IgA (Pi  care l l i  et al . ,  200 1 ). 
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All serological ubjects belong to Arabic  Bedouin fami l ies which in agreement of the study of 
Catassi et aJ . ,  ( 1 999) reporting that the highest pre alence of CD among Arab sub-Saharan. 
Ba ed on the parameter significantl associated with cel iac serology in this study, awareness 
of CD could be due to many factors. Most of the subjects who have information about the 
dJ sea e work in health service, medical students or have relative who suffer from some c lassic 
symptoms of the disease with advising from the doctors not to eat any gluten containing food. 
Moreo er, the awareness inherent in the study itself, since the col lection of the samples 
extended for 6 months, some subjects could have infonned members of their fami ly who 
themselves part ic ipated in  the study at a later stage of the study. 
The prevalence of CD found i n  this study 1 :  86 among UAE nationals of AI Ain city is high 
comparing to prevalence reported in general population of western Europe, the prevalence in  
Denmark was 1 : 330, Finland 1 :  1 30, Gennany 1 : 500, Italy 1 :  1 84 and Netherland 1 :  1 98 
(Guandal in i  & Gupta, 2002). This high prevalence among UAE nationals emphasize the tenn 
CD iceberg that refers to many undiagnosed cases of CD among the general population. 
In F inl and a study of si l ent CD reported 2 1  serological ly positive out of 2427 and 1 1  were 
females (Verkasalo et aI . ,  2005). A study i n  Swedish adults found 1 0  positive subjects out of 
1 894, 7 females and 3 males ( Ivarsson et a i . ,  1 999). The prevalence of in  Argentina among 
premarital subjects was 1 :  1 67, 1 2  out of 2000 were posit ive for EMA IgA, 8 females out of 
996 were positive, so the prevalence among females was double that in males (Gomez et aI . ,  
200 ] ). In  L ibya among school students the prevalence was 2 .24%, 1 5  out of 620 were 
posi tive for tTG (Alarida et ai . ,  2006). No infonnation about the gender of the positive cases. 
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Comparable results of this tudy in adolescents student in eastern Switzerland 1 1  out of 1 450 
students had posItive EMA and! or tTG, 1 0  females out of 87 1  were positive and only one 
male. In  thi stud despite that the number of female subjects was less than males, the 
pre 'alence among females is considered high compared to others studies in the world. 
According to Guiadal in i ,  there are unknown factors increase numbers of asymptomatic CD 
among females, two ob ious factors are the amount of gluten consumption and the extent of 
intestinal damage (Godfrey, 2005) .  There is no study comparing the consumption of wheat in 
females and males in DAE and this study didn't include this parameter in the questionnaire 
data. There are indications that autoimmune diseases share genetic risk factors and many of 
these loci are gender influenced (Ivarson, 2005). Females are l i kely to be genetically more 
vulnerable to environmental exposure factors that affect the immunological process leading to 
CD ( Ivarsson, 2005) .  
Anemia was the main cl inical sign of the cel iac among of the subject, found in  5 of the 
positive subjects, two of the subjects suffered from chronic anemia without any diagnosis of 
their cases. According to the definition of world health organization anemia is a level of 
hemoglobin below than 1 3g1dl in men, below 1 2g1dl in non pregnant women and over the age 
the age 1 5  and, below 1 1 g1dl in pregnant women (Bal l inger, 2006). According to many 
studies anemia is the most single common sign of CD among adults. Study of 200 CD 
patients has shown 5% anemia presentation due to nutritional deficiencies (Howard et aI . ,  
2002). Thus, al l patients who have anemia or i ron deficiency should be screened for CD. Iron 
deficiency usual ly affects 2-5% of adolescents, adult girls and women (Ball inger, 2006). 
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Most of anemic subjects were females which in  agreement with the finding that anemia i s  
more common in females compared with males. 
There are many l imitations in this study; positive subjects refused endoscopy procedure due to 
many reasons, e .g. pregnancy, movement outside Al Ain city, inconvenient time for the 
subjects and worries from this procedure. Therefore, the study is based on serology markers 
of tissue transglutaminase and endomysium 19A. Moreover, the study had l imited recourses 
and there weren't enough resources to do total IgA for al l  the subjects. Total IgA is a 
parameter required to be done at the beginning of the screening for al l  subjects instead of 
doing it only for positive tTG IgG subjects. S ince the study targeted subjects undergoing 
prenuptial test most of the subjects were in the age range of 1 6-30 years of age and older 
subjects are underrepresented compared to the general population. 
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v. CONCLUSION & RECOMMENDATION 
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v. CONCLUSI ON & RECOM MENDATION 
In this tudy gender i the most significant factor associated with CD serological results, with 
much higher pre alence in females ( 1 :43 ) compared to males ( 1 :62 1 )  UAE national adults 
from Al Ain. Those CD patients with si lent/latent form of the disease may be at high risk of 
de eloping anemia, 0 teoporosis and all others compl ications associated with ful l  blown CD 
later in l ife. The low level of awareness of the disease was probably the reason that many 
erological l positi e CD subjects refused endoscopy procedure as a confirmatory diagnostic 
procedure. The result of this study should be conveyed to the health authority for raising the 
av areness of the disease among the health workers and the population in order to adopt ful ly 
functional program of diagnosis and treatment. There are some measures need to be done to 
discover as much as possible the undiagnosed cases in the general population and to increase 
the awareness to the disease, these measures include: 
-Females who suffer from chronic anemia without knowing the reasons should be tested 
for CD to avoid further compl ication of CD. 
-The results of the current study support the concept of CD iceberg which refers to the 
presence of many undiagnosed cases of CD among the general population. Therefore, 
the health workers should be aware that there are many undiagnosed cases of CD 
among U AE nationals. Therefore, they should refer any patients with vague 
symptoms, complications andlor signs suggestive of CD to be investigated as 
suspected CD case. 
-Fol low al l the CD cases and run the CD diagnostic tests on a l l  family members of 
diagnosed cases in order to find any undiagnosed cases within the fami l ies to prevent 
any future compl ication as much as possible. 
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-Make gl uten free diet food avai lable in commercial market so it is easy to the patients to 
find the food and to stick to the diet. 
-To inform the patients that gl uten not only found in the wheat and other grains but there 
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